ChromaDex (CDXC) 10-K 27 Mar 14 2013 FY Annual report Financial data

Document_and_Entity_Informatio

Document and Entity Information (USD $)	12 Months Ended
	Dec. 28, 2013	Mar. 26, 2014	Jun. 29, 2013
Document And Entity Information	'	'	'
Entity Registrant Name	'ChromaDex Corp.	'	'
Entity Central Index Key	'0001386570	'	'
Document Type	'10-K	'	'
Document Period End Date	28-Dec-13	'	'
Amendment Flag	'false	'	'
Current Fiscal Year End Date	'--12-28	'	'
Is Entity a Well-known Seasoned Issuer?	'No	'	'
Is Entity a Voluntary Filer?	'No	'	'
Is Entity's Reporting Status Current?	'Yes	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Entity Public Float	'	'	$47,056,942
Entity Common Stock, Shares Outstanding	'	106,149,101	'
Document Fiscal Period Focus	'FY	'	'
Document Fiscal Year Focus	'2013	'	'

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 28, 2013	Dec. 29, 2012
Current Assets	'	'
Cash	$2,261,336	$520,000
Trade receivables, less allowance for doubtful accounts and returns	838,793	1,940,539
Other receivable	215,000	'
Inventories	2,204,125	5,205,304
Prepaid expenses and other assets	271,445	261,297
Total current assets	5,790,699	7,927,140
Leasehold Improvements and Equipment, net	1,063,239	936,426
Other Noncurrent Assets	'	'
Deposits	43,460	34,773
Long-term investment in affiliate	1,887,844	'
Intangible assets, net	201,650	136,182
Total other noncurrent assets	2,132,954	170,955
Total assets	8,986,892	9,034,521
Current Liabilities	'	'
Accounts payable	1,440,910	3,428,233
Accrued expenses	656,707	876,158
Current maturities of capital lease obligations	138,887	77,259
Customer deposits and other	546,044	310,267
Deferred rent, current	55,586	71,042
Total current liabilities	2,838,134	4,762,959
Capital lease obligations, less current maturities	280,342	148,374
Deferred rent, less current	202,965	129,859
Total Liabilities	3,321,441	5,041,192
Stockholders' Equity	'	'
Common stock, $.001 par value; authorized 150,000,000 shares; issued and outstanding 2013 104,524,738 and 2012 92,140,062 shares	104,525	92,140
Additional paid-in capital	39,697,063	33,617,801
Accumulated deficit	-34,136,137	-29,716,612
Total stockholders' equity	5,665,451	3,993,329
Total liabilities and stockholders' equity	$8,986,892	$9,034,521

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 28, 2013	Dec. 29, 2012
Statement of Financial Position [Abstract]	'	'
Trade receivables, less allowance for doubtful accounts and returns	$9,000	$450,000
Common Stock, Par Value Per Share	$0.00	$0.00
Common Stock, Shares Authorized	150,000,000	150,000,000
Common Stock, Shares, Issued	104,524,738	92,140,062
Common Stock, Shares, Outstanding	104,524,738	92,140,062

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
	Dec. 28, 2013	Dec. 29, 2012
Income Statement [Abstract]	'	'
Sales, net	$10,160,964	$11,610,494
Cost of sales	7,027,828	9,335,057
Gross profit	3,133,136	2,275,437
Operating expenses:	'	'
Sales and marketing	2,357,605	5,520,141
General and administrative	5,117,016	8,391,730
Loss from investment in affiliate	44,961	'
Operating expenses	7,519,582	13,911,871
Operating loss	-4,386,446	-11,636,434
Nonoperating income (expense):	'	'
Interest income	1,251	3,014
Interest expense	-34,330	-29,006
Nonoperating expenses	-33,079	-25,992
Net loss	($4,419,525)	($11,662,426)
Basic and Diluted loss per common share	($0.04)	($0.13)
Basic and Diluted weighted average common shares outstanding	99,987,443	90,268,802

Consolidated_Statement_of_Stoc

Consolidated Statement of Stockholders' Equity (USD $)	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Total
Beginning Balance, Amount at Dec. 31, 2011	$72,940	$20,542,532	($18,054,186)	$2,561,286
Beginning Balance, Shares at Dec. 31, 2011	72,939,996	'	'	'
Issuance of common stock, net of offering costs, Amount	14,900	10,055,338	'	10,070,238
Issuance of common stock, net of offering costs, Shares	14,899,995	'	'	'
Issuance of common stock for vested restricted stock, Amount	1,140	158,460	'	159,600
Issuance of common stock for vested restricted stock, Shares	1,140,000	'	'	'
Repurchase and cancellation of common stock, Amount	-10	-8,190	'	-8,200
Repurchase and cancellation of common stock, Shares	-10,000	'	'	'
Exercise of stock options, Amount	6	3,053	'	3,059
Exercise of stock options, Shares	6,117	'	'	'
Exercise of warrants, Amount	754	156,746	'	157,500
Exercise of warrants,Shares	754,103	'	'	'
Share-based compensation, Amount	2,410	2,709,862	'	2,712,272
Share-based compensation, Shares	2,409,851	'	'	'
Net loss	'	'	-11,662,426	-11,662,426
Ending Balance, Amount at Dec. 29, 2012	92,140	33,617,801	-29,716,612	3,993,329
Ending Balance, Shares at Dec. 29, 2012	92,140,062	'	'	'
Issuance of common stock, net of offering costs, Amount	3,529	2,976,471	'	2,980,000
Issuance of common stock, net of offering costs, Shares	3,529,411	'	'	'
Exercise of stock options, Amount	276	138,093	'	138,369
Exercise of stock options, Shares	276,038	'	'	'
Exercise of warrants, Amount	7,979	1,630,769	'	1,638,748
Exercise of warrants,Shares	7,979,227	'	'	'
Share-based compensation, Amount	600	1,333,930	'	1,334,530
Share-based compensation, Shares	600,000	'	'	'
Net loss	'	'	-4,419,525	-4,419,525
Ending Balance, Amount at Dec. 28, 2013	$104,525	$39,697,063	($34,136,137)	$5,665,451
Ending Balance, Shares at Dec. 28, 2013	104,524,738	'	'	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
	Dec. 28, 2013	Dec. 29, 2012
Cash Flows From Operating Activities	'	'
Net loss	($4,419,525)	($11,662,426)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Depreciation of leasehold improvements and equipment	246,175	328,099
Amortization of intangibles	23,532	15,934
Share-based compensation expense	1,287,917	2,703,253
Loss from disposal of equipment	66,378	1,937
Loss from investment in affiliate	44,961	'
Changes in operating assets and liabilities:	'	'
Trade receivables	1,118,730	-1,216,873
Other receivable	-215,000	'
Inventories	-466,352	-2,299,704
Prepaid expenses and other assets	-62,913	675,602
Accounts payable	-1,618,450	1,177,992
Accrued expenses	-204,891	105,631
Customer deposits and other	235,777	110,574
Deferred rent	57,650	-59,732
Net cash used in operating activities	-3,906,011	-10,119,713
Cash Flows From Investing Activities	'	'
Purchases of leasehold improvements and equipment	-137,349	-24,555
Purchase of intangible assets	-89,000	-52,010
Proceeds from sale of assets	1,000,000	'
Proceeds from investment in affiliate	225,000	'
Net cash provided by (used in) investing activities	998,651	-76,565
Cash Flows From Financing Activities	'	'
Proceeds from issuance of common stock, net of issuance costs	2,980,000	10,229,838
Proceeds from exercise of stock options	138,369	3,059
Proceeds from exercise of warrants	1,638,748	157,500
Repurchase of common stock	'	-8,200
Principal payments on capital leases	-108,421	-86,071
Net cash provided by financing activities	4,648,696	10,296,126
Net increase in cash	1,741,336	99,848
Cash Beginning of Year	520,000	420,152
Cash Ending of Year	2,261,336	520,000
Supplemental Disclosures of Cash Flow Information	'	'
Cash payments for interest	34,330	29,006
Supplemental Schedule of Noncash Investing Activity	'	'
Capital lease obligation incurred for the purchase of equipment	302,017	69,619
Supplemental Schedule of Noncash Share-based Compensation	'	'
Stock awards earned but not issued	'	14,560
Stock awards issued for services rendered in prior period	14,560	'
Changes in stock and warrant awards issued for future services	32,053	23,579
Warrants issued, net of offering costs	'	44,610
Supplemental Schedule of Noncash Activities Related to Sale of BlueScience Consumer Product Line	'	'
Assets transferred	3,526,677	'
Liabilities transferred	368,873	'
Carrying value of long-term investment in affiliate, net of $1,000,000 cash proceeds	$2,157,804	'

Consolidated_Statements_of_Cas1

Consolidated Statements of Cash Flows (Parenthetical) (USD $)	12 Months Ended
	Dec. 28, 2013
Statement of Cash Flows [Abstract]	'
Cash proceeds	$1,000,000

Nature_of_Business_and_Liquidi

Nature of Business and Liquidity	12 Months Ended
	Dec. 28, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Note 1. Nature of Business and Liquidity	'
	Nature of business:  ChromaDex Corporation and its wholly owned subsidiaries, ChromaDex, Inc., Chromadex Analytics, Inc. and Spherix Consulting, Inc. (collectively, the “Company”) are a natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its business model that utilizes its wholly owned business units, including ingredient technologies, catalog of natural product fine chemicals, chemistry and analytical testing services, and product regulatory and safety consulting services.  The Company provides science-based solutions to the nutritional supplement, food and beverage, animal health, cosmetic and pharmaceutical industries.  The Company acquired Spherix Consulting, Inc. on December 3, 2012, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage potential health and regulatory risks.  In 2011, the Company launched its BluScience retail consumer line based on its proprietary ingredients. However, on March 28, 2013, the Company entered into an asset purchase and sale agreement with NeutriSci International Inc. and consummated the sale of BluScience consumer product line to NeutriSci.
	Liquidity:  The Company has incurred a loss from operations of $4,386,446 and a net loss of $4,419,525 for the year ended December 28, 2013, and a net loss of $11,662,426 for the year ended December 29, 2012.  As of December 28, 2013, the cash and cash equivalents totaled approximately $2,261,336.
	Subsequent to the period ended December 28, 2013, the Company assigned a senior convertible secured note issued by NeutriSci to an unrelated party.  At the date of assignment, $2,275,000 remained outstanding on the senior secured convertible note.  The transaction amount was for $1,250,000 and the Company received net proceeds of $1,092,500 after deducting transaction costs.  The Company also agreed to transfer a number of shares of preferred stock of NeutriSci having a value of to $550,000 at a later date.  For more information regarding this assignment transaction is set forth in Note 4 Sale of Product Line and Investment in Affiliate.
	By curtailing certain expenditures, management believes it will be able to support operations of the Company with its current cash, cash equivalents and cash from operations through March, 2015.  However, if the Company determines that it shall require additional financing to further enable it to achieve its long-term strategic objectives, there can be no assurance that such financing will be available on terms favorable to it or at all.  If adequate financing is not available, the Company will further delay, postpone or terminate product and service expansion and curtail certain selling, general and administrative operations.  The inability to raise additional financing may have a material adverse effect on the future performance of the Company.

Significant_Accounting_Policie

Significant Accounting Policies	12 Months Ended
	Dec. 28, 2013
Accounting Policies [Abstract]	'
Note 2. Significant Accounting Policies	'
	Significant accounting policies are as follows:
	Basis of presentation:  The financial statements and accompanying notes have been prepared on a consolidated basis and reflect the consolidated financial position of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated from these financial statements. The Company’s fiscal year ends on the Saturday closest to December 31.  The fiscal years ended December 28, 2013 (referred to as 2013), and December 29, 2012 (referred to as 2012), each consisted of 52 weeks. Every fifth or sixth fiscal year, the inclusion of an extra week occurs due to the Company’s floating year-end date. The fiscal year 2014 will include 53 weeks instead of the normal 52 weeks.
	Accounting estimates:  The preparation of financial statements requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.
	Revenue recognition:  The Company recognizes sales and the related cost of sales at the time the merchandise is shipped to customers or service is performed, when each of the following conditions have been met:  an arrangement exists, delivery has occurred, there is a fixed price, and collectability is reasonably assured.  Discounts, returns and allowances related to sales, including an estimated reserve for the returns and allowances, are recorded as reduction of revenue.
	Shipping and handling fees billed to customers and the cost of shipping and handling fees billed to customers are included in net sales.  For the year ending in December 28, 2013, shipping and handling fees billed to customers were approximately $110,000 and the cost of shipping and handling fees billed to customers was approximately $128,400.  For the year ending in December 29, 2012, shipping and handling fees billed to customers were approximately $109,000 and the cost of shipping and handling fees billed to customers was approximately $123,000.  Shipping and handling fees not billed to customers are recognized as cost of sales.
	Taxes collected from customers and remitted to governmental authorities are excluded from revenue, which is presented on a net basis in the statement of operations.
	Cash concentration:  The Company maintains substantially all of its cash in one bank account.
	Trade accounts receivable:  Trade accounts receivable are carried at original invoice amount less an estimate made for doubtful receivables based on monthly and quarterly reviews of all outstanding amounts.  Management determines the allowance for doubtful accounts by identifying troubled accounts and by using historical experience applied to an aging of accounts.  $433,000 of the allowance amount for the period ended December 29, 2012 represents a hold on the receivables placed by a retailer that carried our BluScience retail consumer product line.  The hold was placed by the retailer as an offset in the event of future returns of the Company’s products and the hold was treated as a reduction of revenue. On March 28, 2013, the Company sold the BluScience retail consumer line to NeutriSci and the related trade accounts receivable including the allowance have been transferred to NeutriSci.  Trade accounts receivable are written off when deemed uncollectible.  Recoveries of trade accounts receivable previously written off are recorded when received.
	Other receivables:  Other receivables are amounts due for payment to the Company other than the Company’s normal customer invoices for merchandise shipped or services performed.  The other receivable amount was from a legal settlement agreement, which the settlement was reached at arbitration form a lawsuit for the violation of the Company’s trademarks.  The counterparty had already remitted the payment to a third party escrow agent prior to December 28, 2013.  This payment was deposited by the Company on January 14, 2014.  The other receivable amount was recorded as a gain in general and administrative expenses in the statement of operations for the period ended December 28, 2013.
	Inventories:  Inventories are comprised of raw materials, work-in-process and finished goods.  They are stated at the lower of cost, determined by the first-in, first-out method (FIFO) method, or market.  The inventory on the balance sheet is recorded net of valuation allowances.  Labor and overhead has been added to inventory that was manufactured or characterized by the Company.  The amounts of major classes of inventory for the periods ended December 28, 2013 and December 29, 2012 are as follows:
			2013		2012
	Reference standards		$	1,769,160	$	1,614,755
	Bulk ingredients			694,965		432,230
	Dietary supplements – raw materials			-		401,809
	Dietary supplements – work in process			-		465,253
	Dietary supplements – finished goods			-		2,657,257
				2,464,125		5,571,304
	Less valuation allowance			260,000		366,000
			$	2,204,125	$	5,205,304
	The Company regularly reviews inventories on hand and records a provision for slow-moving and obsolete inventory, inventory not meeting quality standards and inventory subject to expiration. The provision for slow-moving and obsolete inventory is based on current estimates of future product demand, market conditions and related management judgment. Any significant unanticipated changes in future product demand or market conditions that vary from current expectations could have an impact on the value of inventories.
	Intangible assets:  Intangible assets include licensing rights and are accounted for based on the fair value of consideration given or the fair value of the net assets acquired, whichever is more reliable. Intangible assets with finite useful lives are amortized using the straight-line method over a period of 10 years, or, for licensed patent rights, the remaining term of the patents underlying licensing rights (considered to be the remaining useful life of the license).
	Leasehold improvements and equipment:  Leasehold improvements and equipment are carried at cost and depreciated on the straight-line method over the lesser of the estimated useful life of each asset or lease term. Leasehold improvements and equipment are comprised of leasehold improvements, laboratory equipment, furniture and fixtures, and computer equipment. Depreciation on equipment under capital lease is included with depreciation on owned assets.  The costs incurred for a routine maintenance to keep the asset operating at its present condition are expensed.  Useful lives of leasehold improvements and equipment for each of the category are as follows:
		Useful Life
	Leasehold improvements	Until the end of the lease term
	Computer equipment	3 to 5 years
	Furniture and fixtures	7 years
	Laboratory equipment	10 years
	Long-lived assets are reviewed for impairment on a periodic basis and when changes in circumstances indicate the possibility that the carrying amount may not be recoverable.  Long-lived assets are grouped at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets.  If the forecast of undiscounted future cash flows is less than the carrying amount of the assets, an impairment charge would be recognized to reduce the carrying value of the assets to fair value.  If a possible impairment is identified, the asset group’s fair value is measured relying primarily on a discounted cash flow methodology.
	Long-term investment in affiliate: The Company accounts for its investment in affiliate under the equity method.  The Company records equity method adjustments in gains (losses) on equity method investments, net, and may do so with up to a three-month lag, pending on the timely availability of financial information of the investee.  Equity method adjustments include: our proportionate share of investee income or loss, gains or losses resulting from investee capital transactions, and other adjustments required by the equity method.  The long-term investment in affiliate is subject to a periodic impairment review and is considered to be impaired when a decline in carrying value is judged to be other-than-temporary.  Evidence of a loss in value might include (i) absence of an ability recover the carrying amount of the investment or (ii) inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment.
	Customer deposits and other:  Customer deposits and other represent either (i) cash received from customers in advance of product shipment or delivery of services; or (ii) cash received from government as research grants, which the Company has yet to complete the research activities.
	The cash received from government as research grants is recognized as a liability until the research is performed.  Other than a nominal management fee, which the Company is entitled to earn when the research is performed, the research activities related to the grants are excluded from revenue and are presented on a net basis in the statement of operations.
	Income taxes:  Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards and deferred liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.
	The Company has not recorded a reserve for any tax positions for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility. The Company files tax returns in all appropriate jurisdictions, which include a federal tax return and various state tax returns. Open tax years for these jurisdictions are 2010 to 2013, which statutes expire in 2014 to 2016, respectively. When and if applicable, potential interest and penalty costs are accrued as incurred, with expenses recognized in general and administrative expenses in the statements of operations. As of December 28, 2013, the Company has no liability for unrecognized tax benefits.
	Research and development costs:  Research and development costs consist of direct and indirect costs associated with the development of the Company’s technologies. These costs are expensed as incurred.  Research and development costs for the periods ended December 28, 2013 and December 29, 2012 were approximately $134,000 and $142,000, respectively.
	Advertising: The Company expenses the production costs of advertising the first time the advertising takes place.   Advertising expense for the periods ended December 28, 2013 and December 29, 2012 were approximately $355,000 and $2,565,000, respectively.
	Share-based compensation:  The Company has an Equity Incentive Plan under which the Board of Directors may grant restricted stock or stock options to employees and non-employees.  For employees, share-based compensation cost is recorded for all option grants and awards of non-vested stock based on the grant date fair value of the award, and is recognized over the period the employee is required to provide services for the award.  For non-employees, share-based compensation cost is recorded for all option grants and awards of non-vested stock and is remeasured over the vesting term as earned.  The expense is recognized over the period the non-employee is required to provide services for the award.
	The Company recognizes compensation expense over the requisite service period using the straight-line method for option grants without performance conditions.  For stock options that have both service and performance conditions, the Company recognizes compensation expense using the graded attribution method.  Compensation expense for stock options with performance conditions is recognized only for those awards expected to vest.
	From time to time, the Company awards shares of its common stock to non-employees for services provided or to be provided.  If the fair value of services received is more reliably measurable than the fair value of the stock awarded, the fair value of the services received is used to measure the award.  In contrast, if the fair value of the stock issued is more reliably measurable, than the fair value of services received, the award is measured based on the fair value of the stock awarded.  Since these stock awards are fully vested and non-forfeitable, upon issuance the measurement date for the award is usually reached on the date of the award.  The measured fair value of the award is amortized over the period the service is provided.
	Fair Value Measurement: The Company follows the provisions of the accounting standard which defines fair value, establishes a framework for measuring fair value and enhances fair value measurement disclosure. Under these provisions, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.
	The standard establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use on unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is described below:
	Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
	Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.
	Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
	Financial instruments:  The carrying amounts reported in the balance sheet for accounts receivable and accounts payable approximate their fair values.  The carrying amounts reported in the balance sheet for capital lease obligations are present values of the obligations, excluding the interest portion.  Capital lease obligations with maturities less than one year are classified as current liabilities.

Earnings_Per_Share

Earnings Per Share	12 Months Ended
	Dec. 28, 2013
Earnings Per Share [Abstract]	'
Note 3. Earnings Per Share	'
	Potentially dilutive common shares consist of the incremental common shares issuable upon the exercise of common stock options for the period ending in December 28, 2013 and common stock options and warrants for the period ending in December 29, 2012.   For all periods presented, the basic and diluted shares reported are equal because the common shares equivalents are anti-dilutive. Below is a tabulation of the potentially dilutive securities that were “in the money” for the periods ended December 28, 2013 and December 29, 2012.
		Years Ended
		2013		2012
	Basic weighted average common shares outstanding		99,987,443		90,268,802
	Warrants and options in the money, net		605,567		5,720,320
	Weighted average common shares outstanding assuming dilution		100,593,010		95,989,122
	Total warrants and options that were not “in the money” at December 28, 2013 and December 29, 2012 were 145,000 and 14,914,696, respectively.

Sale_of_Product_Line_and_Inves

Sale of Product Line and Investment in Affiliate	12 Months Ended
	Dec. 28, 2013
Sale Of Product Line And Investment In Affiliate	'
Note 4. Sale of Product Line and Investment in Affiliate	'
	On March 28, 2013, the Company entered into an asset sale agreement with NeutriSci and consummated the sale of the BluScience consumer product line to NeutriSci.  The Company is using the cost recovery method to account for the sale transaction, which is estimated at approximately $3,157,804. The consideration received consists of the following: (a) a $250,000 cash payment, which NeutriSci paid as a deposit in February 2013; (b) an additional $250,000 cash payment, which was paid at the closing of the sale;  (c) an additional cash payment of $500,000 due no later than 60 days after the closing of the sale, which has been fully paid as of December 28, 2013; (d) a $2,500,000 senior convertible secured note (the “Senior Note”) (convertible into 625,000 shares of NeutriSci Series I Preferred Stock) payable in quarterly installments of $416,667 beginning August 15, 2013, of which a partial payment of $225,000 was received for the first installment on September 27, 2013 and an amendment to extend the repayment schedule was executed on October 18, 2013; and (e) 669,708 shares of Series I Preferred Shares that are convertible into 2,678,832 Class A common shares of NeutriSci, representing an aggregate of 19% of the NeutriSci shares at a deemed price for each Class A common share of $1.00 per share at March 28, 2013.  The transaction documents contain certain equity blockers that preclude the Company’s ownership in NeutriSci in excess of 9.99% and 19% without obtaining a waiver from NeutriSci.  The Company is contractually entitled to receive revenue through a royalty on 6% of future net sales of BluScience products as well as a supply agreement with NeutriSci for the Company’s patented pTeroPure pterostilbene.  As of December 28, 2013, the Company did not have any sales to NeutriSci under this supply agreement for pTeroPure pterostilbene.
	The Company has applied the equity method of accounting due to a significant influence that it has obtained from the financial instruments noted above, and the carrying value, which includes the Senior Note, is reflected as long-term investment in affiliate in the Company’s consolidated balance sheet as of December 28, 2013.  The initial carrying value of this investment recognized as of March 28, 2013 was $2,157,804, which is the Company’s unrecovered cost or the difference between the net assets transferred to NeutriSci and the initial monetary consideration received.  Management believed that $2,157,804 was the appropriate aggregate carrying value for the investment in affiliate under the cost recovery method, considering the fact that (a) NeutriSci is a start-up company and has historically recorded significant operating losses; (b) lack of operations beyond the acquired BluScience assets and the uncertainty surrounding the repayment of the note based on both ongoing sales of BluScience by NeutriSci as well as NeutriSci’s plans to raise additional funds to support the business and repayment of the note; and (c) the Company cannot reasonably estimate the collectability of the note receivable.  The 669,708 shares of Series I Preferred Shares and the senior convertible secured note were accounted for as one long-term investment in NeutriSci.  Under the cost recovery method, no gain on the sale will be recognized until the Company’s cost basis in the net assets transferred has been recovered.  Prospective collection of payments under the note will be charged against the carrying value of the long-term investment in affiliate. The below table illustrates how the carrying value was determined.
		At March 28, 2013
	Assets transferred
	Trade receivables, less allowance for returns	$	(16,984	)
	Inventories		3,467,530
	Prepaid expenses and other assets		76,131
	Total assets transferred		3,526,677
	Liabilities transferred
	Accounts payable		368,873
	Total liabilities transferred		368,873
	Total net assets transferred	$	3,157,804
	Initial monetary consideration received
	Cash	$	500,000
	Non-trade receivable		500,000
	Total initial monetary consideration received	$	1,000,000
	Carrying Value of Long Term Investment in Affiliate	$	2,157,804
	The Company has elected to record equity method adjustments in gains (losses) on the investment in NeutriSci, with a three-month lag, as the financial information of NeutriSci was not available in a timely manner.  Due to the three-month lag, the loss reported for the Company’s period ended December 28, 2013 represents our percentage interest in the results of NeutriSci’s operations from April 1, 2013 to September 30, 2013.  The Company expects that the effect of the three-month lag will not result in a material difference in the accounting as the Company expects its ownership in NeutriSci to continue to decrease in the future.
	Sales, gross profit, net loss of NeutriSci for the six months ended September 30, 2013 and the changes in carrying value and the Company ownership percentage through December 28, 2013 are summarized as follows:
		30-Sep-13
	Sales	$	36,451
	Gross profit		13,310
	Net loss	$	(813,212	)
	Changes in Carrying Value and Ownership Percentage for ChromaDex Corporation
		Carrying Value			Ownership
					Percentage
	At March 28, 2013	$	2,157,804			5.7	%
	Company's share of NeutriSci's loss through September 30, 2013		(44,961	)		-
	Proceeds from investment in affiliate		(225,000	)		-
	At December 28, 2013	$	1,887,844			4.9	%
	The Company's December 28, 2013 ownership percentage presented in the above table is derived using NeutriSci’s financial information through September 30, 2013.
	During the year ended December 28, 2013, the Company fully received the $500,000 cash payment that was reflected as non-trade receivable as of March 28, 2013.  Also, during the year ended December 28, 2013, the Company received a partial payment of $225,000 for the first installment of $416,667 that was due under the Senior Note.
	Subsequent event – Sale of Senior Secured Convertible Note
	Subsequent to the year ended December 28, 2013, the Company assigned the Senior Note to an unrelated third party for $1,250,000.  $2,275,000 remained outstanding on the Senior Note at the date of the assignment.  The Company also paid legal fee of $7,500 out of the proceeds of the purchase price.  The Company also agreed to transfer to the third party a number of shares of preferred stock of NeutriSci having a value of $500,000 upon the earlier of (a) December 31, 2014; or (b) the consummation by NeutriSci of any action resulting in the shares of its common stock being listed on an exchange.  There is no recourse provision to the Company associated with the assignment of the note.  In connection with the assignment of the note, the Company paid Palladium Capital Advisors, LLC as a placement agent a cash fee of $150,000 and agreed to transfer to Palladium a number of shares of preferred stock of NeutriSci having a value of $50,000 upon the consummation by NeutriSci of any action resulting in the shares of its common stock being listed on an exchange.
	Valuation assessment of Investment
	As of December 28, 2013, the Company has determined that there is no other-than-temporary impairment of the carrying amounts of its investment in NeutriSci.  The Company will continue to monitor NeutriSci’s performance and evaluate if there are any such events or indicators to consider.

Intangible_Assets

Intangible Assets	12 Months Ended
	Dec. 28, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Note 5. Intangible Assets	'
	Intangible assets consisted of the following:
			2013					2012
			Gross Carrying			Accumulated		Gross Carrying		Accumulated
			Amount			Amortization		Amount		Amortization
	Amortized intangible assets:
	License agreements and other	$	1,075,285		$	873,635	$	986,285	$	850,103
	Amortization expense on amortizable intangible assets included in the consolidated statement of operations for the year ended December 28, 2013 and December 29, 2012 was approximately $24,000 and $16,000, respectively.  The unamortized expense is expected to be recognized over a weighted average period of 7.9 years as of December 28, 2013.
	Estimated aggregate amortization expense for each of the next five years is as follows:
	Years ending December:
	2014		$	28,000
	2015			28,000
	2016			28,000
	2017			28,000
	2018			23,000
	Thereafter			67,000
			$	202,000

Leasehold_Improvements_and_Equ

Leasehold Improvements and Equipment	12 Months Ended
	Dec. 28, 2013
Leasehold Improvements And Equipment	'
Note 6. Leasehold Improvements and Equipment	'
	Leasehold improvements and equipment consisted of the following:
		2013		2012
	Laboratory equipment	$	2,782,364	$	2,439,688
	Leasehold improvements		491,125		403,971
	Computer equipment		372,851		363,739
	Furniture and fixtures		18,313		18,313
	Office equipment		7,877		7,877
	Construction in progress		40,126		106,080
			3,712,656		3,339,668
	Less accumulated depreciation		2,649,417		2,403,242
		$	1,063,239	$	936,426
	Depreciation expense on leasehold improvements and equipment included in the consolidated statement of operations for the year ended December 28, 2013 and December 29, 2012 was approximately $246,000 and $328,000, respectively.

Capitalized_Lease_Obligations

Capitalized Lease Obligations	12 Months Ended
	Dec. 28, 2013
Capitalized Lease Obligations	'
Note 7. Capitalized Lease Obligations	'
	The Company leases equipment under capitalized lease obligations with a total cost of $695,461 and $381,888 and accumulated amortization of $136,358 and $90,960 as of December 28, 2013 and December 29, 2012, respectively.
	Minimum future lease payments under capital leases as of December 28, 2013, are as follows:
	Year ending December:
	2014	$	172,948
	2015		112,794
	2016		99,902
	2017		79,054
	2018		30,198
	Total minimum lease payments		494,896
	Less amount representing interest at a rate of approximately 9.8% per year		75,667
	Present value of net minimum lease payments		419,229
	Less current portion		138,887
	Long-term obligations under capital leases	$	280,342
	Interest expense related to capital leases was approximately $34,000 and $29,000 for the years ended December 28, 2013 and December 29, 2012, respectively.

Income_Taxes

Income Taxes	12 Months Ended
	Dec. 28, 2013
Income Taxes	'
Note 8. Income Taxes	'
	A reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate of 34% for 2013 and 2012 compared to the Company’s income tax expense for the years ended December 28, 2013 and December 29, 2012 is as follows:
		2013			2012
	Income tax expense (benefit) at statutory rate	$	(1,503,000	)	$	(3,965,000	)
	(Increase) decrease resulting from:
	State income taxes, net of federal tax effect		(189,000	)		(428,000	)
	Nondeductible expenses		117,000			134,000
	Change in effective tax rate		(166,000	)		194,000
	Change in valuation allowance		1,732,000			4,136,000
	Other		9,000			(71,000	)
		$	-		$	-
	The deferred income tax assets and liabilities consisted of the following components as of December 28, 2013 and December 29, 2012:
		2013			2012
	Deferred tax assets:
	Net operating loss carryforward	$	8,953,000		$	8,512,000
	Stock options and restricted stock		1,945,000			1,679,000
	Investment in affiliate related to BluScience transaction		1,187,000			-
	Inventory reserve		100,000			138,000
	Allowance for doubtful accounts		3,000			169,000
	Accrued expenses		164,000			134,000
	Intangibles		36,000			48,000
	Deferred rent		99,000			76,000
			12,487,000			10,756,000
	Less valuation allowance		12,361,000			10,629,000
			126,000			127,000
	Deferred tax liabilities:
	Leasehold improvements and equipment		(100,000	)		(101,000	)
	Prepaid expenses		(26,000	)		(26,000	)
			(126,000	)		(127,000	)
		$	-		$	-
	The Company has tax net operating loss carryforwards and other tax attributes available to offset future federal taxable income and future state taxable income of approximately $23,329,000 and $19,227,000, respectively which begin to expire in the year ending December 31, 2023 and 2014, respectively.  The net operating loss can be carried forward up to 20 years for federal tax returns and from 5 to 20 years for various state tax returns.  Under the Internal Revenue Code, certain ownership changes may subject the Company to annual limitations on the utilization of its net operating loss carryforward.  The Company has determined that the stock issued in the year 2010 created a change in control under the Internal Revenue Code Section 382.  This limitation when applying to future taxable income is not expected to be significant. The Company will continue to analyze the potential impact of any additional transactions undertaken upon the utilization of the net operating losses on a go forward basis.

Employee_Equity_Incentive_Plan

Employee Equity Incentive Plan	12 Months Ended
	Dec. 28, 2013
Employee Equity Incentive Plan	'
Note 9. Employee Equity Incentive Plan	'
	Stock Option Plans
	At the discretion of the Company’s compensation committee (the “Compensation Committee”), and with the approval of the Company’s board of directors (the “Board of Directors”), the Company may grant options to purchase the Company’s common stock to certain individuals from time to time. Management and the Compensation Committee determine the terms of awards which include the exercise price, vesting conditions and expiration dates at the time of grant. Expiration dates for stock options are not to exceed 10 years from their date of issuance. The Company, under its Second Amended and Restated 2007 Equity Incentive Plan, is authorized to issue stock options that total no more than 20% of the shares of common stock issued and outstanding, as determined on a fully diluted basis.  Beginning in 2007, stock options were no longer issuable under the Company’s 2000 Non-Qualified Incentive Stock Plan.  The remaining amount available for issuance under the Second Amended and Restated 2007 Equity Incentive Plan totaled 6,953,940 at December 28, 2013. The stock option awards generally vest ratably over a four-year period following grant date after a passage of time.  However, some stock option awards are performance based and vest based on the achievement of certain criteria established by the Compensation Committee, subject to approval by the Board of Directors.
	The fair value of the Company’s stock options was estimated at the date of grant using the Black-Scholes based option valuation model.  The table below outlines the weighted average assumptions for options granted to employees during the years ended December 28, 2013 and December 29, 2012.
	Year Ended December	2013			2012
	Volatility		32.75	%		33.22	%
	Expected dividends		0	%		0	%
	Expected term	6.0 years			5.8 years
	Risk-free rate		1.51	%		0.96	%
	The Company calculated expected volatility from the volatility of publicly held companies in similar industries, as the historical volatility of the Company’s common stock does not cover the period equal to the expected life of the options.  The dividend yield assumption is based on the Company’s history and expectation of future dividend payouts on the common stock.  The risk-free interest rate is based on the implied yield available on U.S. treasury zero-coupon issues with an equivalent remaining term.  For the expected term, the Company used SEC Staff Accounting Bulletin No. 107 simplified method since most of the options granted were “plain vanilla” options with following characteristics: (i) the share options are granted at the market price on the grant date; (ii) exercisability is conditional on performing service through the vesting date on most options; (iii) If an employee terminates service prior to vesting, the employee would forfeit the share options; (iv) if an employee terminates service after vesting, the employee would have 30 days to exercise the share options; and (v) the share options are nontransferable and nonhedgeable.  The estimation process for the fair value of performance based stock options was the same as for service period based options.
	1) Service Period Based Stock Options
	The majority of options granted by the Company are comprised of service based options granted to employees.  These options vest ratably over a defined period following grant date after a passage of a service period.
	The following table summarizes service period based stock options activity at December 28, 2013 and changes during the year then ended:
					Weighted Average
								Remaining		Aggregate
		Number of			Exercise			Contractual		Intrinsic
		Shares			Price			Term		Value
	Outstanding at December 29, 2012		12,202,558		$	1.08
	Options Granted		805,000			0.81
	Options Exercised		(26,038	)		0.51
	Options Expired		(75,000	)		0.5
	Options Forfeited		(792,865	)		1.19
	Outstanding at December 28, 2013		12,113,655		$	1.06			7.43	$	6,513,219
	Exercisable at December 28, 2013		8,184,312		$	1.14			6.76	$	3,767,235
	During the year ended December 29, 2012, the Company granted option awards to 7 directors and 2 employees who are all accredited investors at an exercise price of $0.945, on the condition that certain option awards with exercise prices of $1.50 or higher, which the Company had previously granted are terminated.  Such directors and employees accepted these conditional option awards and agreed to terminate previously granted options to purchase an aggregate of 7,765,512 shares at exercise prices of $1.50 or higher and receive new option awards to purchase an aggregate of 4,777,878 shares at an exercise price of $0.945.  The incremental compensation cost, which is the excess of the fair value of the replacement awards over the fair value of the cancelled awards at the cancellation date, was measured using the Black-Scholes based option valuation model.  The total incremental compensation cost was $970,071 and this cost together with the unrecognized compensation cost of the cancelled awards will be amortized over the vesting periods of replacement awards which range from 1 to 3 years.  The existing expense of the cancelled awards through cancellation date remains and is not reversed.
	The aggregate intrinsic values in the table above are before income taxes, based on the Company’s closing stock price of $1.60 on the last day of business for the year ended December 28, 2013.  The weighted average fair value of options granted during the years ended December 28, 2013, and December 29, 2012 was $0.29, and $0.27 respectively.  The aggregate intrinsic value for options exercised during the years ended December 28, 2013, and December 29, 2012 was approximately $7,000 and $1,000 respectively.
	2) Performance Based Stock Options
	The Company also grants stock option awards that are performance based and vest based on the achievement of certain criteria established from time to time by the Compensation Committee.  If these performance criteria are not met, the compensation expenses are not recognized and the expenses that have been recognized will be reversed.
	The following table summarizes performance based stock options activity at December 28, 2013 and changes during the year then ended:
					Weighted Average
								Remaining		Aggregate
		Number of			Exercise			Contractual		Intrinsic
		Shares			Price			Term		Value
	Outstanding at December 29, 2012		145,834		$	1.59
	Options Granted		200,000			0.63
	Options Exercised		-			-
	Options Expired		-			-
	Options Forfeited		(145,834	)		1.59
	Outstanding at December 28, 2013		200,000		$	0.63			9.08	$	194,000
	Exercisable at December 28, 2013		-		$	-			-	$	-
	The aggregate intrinsic value in the table above are before income taxes, based on the Company’s closing stock price of $1.60 on the last day of business for the period ended December 28, 2013.  The weighted average fair value of options granted during the year ended December 28, 2013 was $0.22.  The Company did not grant any performance based stock options during the year ended December 29, 2012.
	As of December 28, 2013, there was approximately $1,628,000 of total unrecognized compensation expense related to non-vested share-based compensation arrangements granted under the plans for employee stock options. That cost is expected to be recognized over a weighted average period of 2.32 years.  The realized tax benefit from stock options for the years ended December 28, 2013, and December 29, 2012 was $0, based on the Company’s election of the “with and without” approach.
	Restricted Stock with Market Conditions
	Restricted stock awards granted by the Company to employees generally have market vesting conditions that are unique to each award.
	The following table summarizes activity of restricted stock awards granted to employees at December 28, 2013 and changes during the twelve months then ended:
					Weighted Average
					Award-Date
		Shares			Fair Value
	Unvested shares at December 29, 2012		500,000		$	0.69
	Granted		-			-
	Vested		-			-
	Forfeited		-			-
	Unvested shares at December 28, 2013		500,000		$	0.69
	Expected to Vest as of December 28, 2013		500,000		$	0.69
	Certain restricted stock awards had market conditions.  The fair values of these restricted stock awards were estimated at the dates of award using the Hull-White based binomial valuation model.  The table below outlines the weighted average assumptions of these market conditioned restricted stock awarded to employees during the year ended December 29, 2012.
	Year Ended December 29, 2012	2012
	Expected Term		3
	Expected Volatility		69.98	%
	Expected Dividends		0	%
	Risk Free Rate of Return		0.39	%
	The Company calculated expected volatility from the volatility of publicly held companies in similar industries as well as the historical volatility of the Company’s common stock.  Less weight was assigned to the volatility of the Company’s common stock as the historical volatility of Company’s common stock covers only about four and a half years in a thinly traded market.  The dividend yield assumption is based on the Company’s history and expectation on future dividend payouts on the common stock.  The risk-free interest rate is based on the implied yield available on U.S. treasury zero-coupon issues with an equivalent remaining term.  The Company used the expected vesting period of the restricted stock for estimating the expected term of the restricted stock.
	Certain restricted stock awards had both market and service conditions and the awards become vested on the satisfaction of either condition.  The fair values of these restricted stock awards were estimated at the date of award using the Company’s stock price as the service condition prevailed over the market condition.
	On February 13, 2012, William Spengler, our former President, ceased serving in all positions he held with the Company.  1,000,000 restricted shares of our common stock held by Mr. Spengler were forfeited.  Expense recognized related to this forfeited restricted stock award was reversed during the year ended December 29, 2012, as the vesting conditions established by the Company, including continuous employment through November 15, 2013, were not met.  The reversed expense amount the Company had recognized through December 31, 2011 was $476,411.
	On February 7, 2012, the Company awarded 1,000,000 shares of restricted stock to our former Chief Executive Officer and President, Jeffrey Himmel and on February 21, 2012, the Company awarded 750,000 shares of restricted stock to our former Chief Operating Officer, Debra Heim.  On June 11, 2012, both Mr. Himmel and Ms. Heim ceased serving in all positions held with the Company and restricted shares held by Mr. Himmel and Ms. Heim were forfeited.  Expense recognized related to these forfeited restricted stock awards was reversed.
On June 6, 2012, the Company awarded 250,000 shares of restricted stock to each of our Chief Executive Officer, Frank Jaksch and our Chief Financial Officer, Thomas Varvaro.  These shares shall vest upon the earlier to occur of the following: (i) the market price of the Company’s stock exceeds a certain price, or (ii) one of other certain triggering events, including the termination of Mr. Jaksch or Mr. Varvaro for any reason.  As of December 29, 2012, these shares have not been vested.
As of December 28, 2013, the Company did not have any unrecognized compensation expense related to restricted stock awards to employees.
Stock Awards
From time to time, the Company awards shares of its common stock to executives and members of the Board of Directors as part of its overall compensation program.  On February 7, 2012, the Company awarded 100,000 shares of common stock to Jeffrey Himmel, our former Chief Executive Officer and President, pursuant to an employment agreement with Mr. Himmel.  The fair value of these awarded shares was estimated at the date of award using the Company’s stock price.  Since these shares are immediately vested, the award is deemed to be fully earned upon issuance and the full fair value of $94,000 was expensed on the date of award.  On February 21, 2012, the Company awarded 75,000 shares of common stock to Debra Heim, our former Chief Operating Officer, pursuant to an employment agreement with Ms. Heim.  The fair value of these awarded shares was estimated at the date of award using the Company’s stock price.  Since these shares are immediately vested, the award is deemed to be fully earned upon issuance and the full fair value of $60,000 was expensed on the date of award.  On June 6, 2012, the Company awarded 500,000 shares of common stock to each of Michael Brauser and Barry Honig, who are Co-Chairmen of the Board of Directors.  The fair value of these awarded shares was estimated at the date of award using the Company’s stock price.  Since these shares are immediately vested, the awards are deemed to be fully earned upon issuance and the full fair value of $690,000, or $345,000 each was expensed on the date of award.
For employee share-based compensation, the Company recognized share-based compensation expense of approximately $958,000 in general and administrative expenses in the statement of operations for the year ended December 28, 2013.  The Company recognized $1,498,000 in share-based compensation expense for the year ended December 29, 2012.

NonEmployee_ShareBased_Compens

Non-Employee Share-Based Compensation	12 Months Ended
	Dec. 28, 2013
Non-Employee Share-Based Compensation	'
Note 10. Non-Employee Share-Based Compensation [Text Block]	'
	Stock Option Plans
	At the discretion of management, working with the Compensation Committee, and with approval of the Board of Directors, the Company may grant options to purchase the Company’s common stock to certain individuals from time to time who are not employees of the Company.  These options are granted under the Second Amended and Restated 2007 Equity Incentive Plan of the Company and are granted on the same terms as those being issued to employees.  Stock options granted to non-employees are accounted for using the fair value approach.  The fair value of non-employee option grants are estimated using the Black-Scholes option-pricing model and are re-measured over the vesting term until earned.  The estimated fair value is expensed over the applicable service period.
	The following table summarizes activity of stock options granted to non-employees at December 28, 2013 and changes during the year then ended:
					Weighted Average
							Remaining		Aggregate
		Number of			Exercise		Contractual		Intrinsic
		Shares			Price		Term		Value
	Outstanding at December 29, 2012		1,097,300		$	1.23
	Options Granted		-			-
	Options Exercised		(250,000	)		0.5
	Options Forfeited		-			-
	Outstanding at December 28, 2013		847,300		$	1.44		5.74	$	131,627
	Exercisable at December 28, 2013		847,300		$	1.44		5.74	$	131,627
	The aggregate intrinsic values in the table above are before income taxes, based on the Company’s closing stock price of $1.60 on the last day of business for the year ended December 28, 2013.  The aggregate intrinsic value for options exercised during the year ended December 28, 2013 was $35,000.  There were no options exercised during the year ended December 29, 2012.
	As of December 28, 2013, the Company did not have any unrecognized compensation expense related to non-vested share-based compensation arrangements granted under the plans for non-employee stock options.
	Stock Awards
	During the year ended December 28, 2013, the Company awarded an aggregate of 600,000 shares of the Company’s common stock that were fully vested and non-refundable to non-employees.  The fair values of the awards were based on the trading price of the Company’s stock on the date of issuance.  The expense the Company recognized for these awards was approximately $325,000 for the year ended December 28, 2013.  During the year ended December 29, 2012, the Company awarded an aggregate of 1,234,851 shares and recognized a total expense of approximately $790,000.
	Warrant Awards
	During the year ended December 28, 2013, the Company recognized an expense of approximately $4,094 for the warrants that were previously awarded to a certain non-employee during the year ended December 29, 2012.  During the year ended December 28, 2013, these warrants were exercised and the Company issued 74,186 shares of common stock.  The non-employee who held these warrants elected a cashless exercise pursuant to the provisions of the warrants and received 74,186 shares of common stock in lieu of 250,000 shares for a cash payment of $0.75 per share.  The intrinsic value of the warrants exercised was $90,507.
	The fair value of these warrants was estimated at the date of award using the Black-Scholes based valuation model.  The table below outlines the assumptions for the warrants granted.
	Year Ended December 29, 2012	2012
	Volatility		28.2	%
	Expected dividends		0	%
	Expected term	2.0 years
	Risk-free rate		0.27	%
	The Company calculated expected volatility from the volatility of publicly held companies in similar industries. The Company did not use the volatility of the Company’s common stock as the historical volatility of Company’s common stock covers only about four and a half years in a thinly traded market.  The dividend yield assumption is based on the Company’s history and expectation of future dividend payouts on the common stock.  The risk-free interest rate is based on the implied yield available on U.S. treasury zero-coupon issues with an equivalent remaining term.  The expected term of the warrants represents the contractual terms.  For the year ended December 29, 2012, the expense the Company recognized for this warrant award was $4,731.
	For non-employee share-based compensation, the Company recognized share-based compensation expense of approximately $330,000 in general and administrative expenses in the statement of operations for the year ended December 28, 2013. The Company recognized approximately $1,206,000 in share-based compensation expense for the year ended December 29, 2012.

Stock_Issuance

Stock Issuance	12 Months Ended
	Dec. 28, 2013
Stock Issuance	'
Note 11. Stock Issuance	'
	On October 17, 2013, the Company sold an aggregate of 2,941,176 shares of the Company’s common stock, with gross proceeds to the Company of $2,500,000 to a certain strategic accredited investor pursuant to a subscription agreement. Each share of common stock was sold for a purchase price of $0.85 per share.  There is no put provision to the Company associated with the issuance of the Company’s common stock.
	On October 18, 2013, the Company sold an aggregate of 588,235 shares of the Company’s common stock, with gross proceeds to the Company of $500,000 to a certain strategic accredited investor pursuant to a subscription agreement. Each share of Common Stock was sold for a purchase price of $0.85 per share on the same terms of the investment made by the strategic accredited investor on October 17, 2013. A cash fee in the amount of $20,000 was paid to a placement agent in connection with this $500,000 investment.
	On January 31, 2012, the Company entered into a definitive agreement with investors in a registered direct offering of common stock at a price per share of $0.75.  On February 9, 2012, the registered direct offering was consummated and the Company sold 9,966,666 shares of common stock at a price per share of $0.75 for gross proceeds of $7,475,000, or net proceeds of $6,739,498 after deducting offering costs.  As a part of the offering commission to its placement agent, the Company issued warrants to purchase 300,000 shares of the Company’s common stock to the placement agent, Aegis Capital Corp. and its designees.  These warrants have an exercise price of $0.85 per share, a term of 2.5 years and a cashless exercise feature.  The aggregate estimated fair value of these warrants was $44,610 and these warrants were determined to be equity awards.  The fair value was estimated at the date of issuance using the Black-Scholes based valuation model.  The table below outlines the assumptions for the warrants issued to Aegis Capital Corp. and its designees.
	Year Ended December 29, 2012	2012
	Volatility		29.7	%
	Expected dividends		0	%
	Expected term	2.5 years
	Risk-free rate		0.28	%
	The Company calculated expected volatility from the volatility of publicly held companies in similar industries.  The dividend yield assumption is based on the Company’s history and expectation of future dividend payouts on the common stock.  The risk-free interest rate is based on the implied yield available on U.S. treasury zero-coupon issues with an equivalent remaining term.  The expected term of the warrants represents the contractual terms.
	In addition, on January 31, 2012, the Company entered into an agreement with investors, including several members of the Company’s management, for the sale of restricted shares of common stock at a price per share of $0.75 per share in a private placement.  On February 10, 2012, the sale to investors in a private placement was consummated and the Company sold 4,933,329 restricted shares of common stock at a price per share of $0.75 per share for gross proceeds of $3,699,997, or net proceeds of $3,330,740 after deducting offering costs.

Warrants

Warrants	12 Months Ended
	Dec. 28, 2013
Warrants	'
Note 12. Warrants	'
	The following table summarizes activity of warrants at December 28, 2013 and changes during the year then ended:
					Weighted Average
							Remaining		Aggregate
		Number of			Exercise		Contractual		Intrinsic
		Shares			Price		Term		Value
	Outstanding at December 29, 2012		10,056,914		$	0.72
	Warrants Granted		-			-
	Warrants Exercised		(8,338,564	)		0.25
	Warrants Expired		(1,718,350	)		3
	Outstanding at December 28, 2013		-		$	-		-	$	-
	Exercisable at December 28, 2013		-		$	-		-	$	-
	During the year ended December 28, 2013, 7,803,564 warrants with an exercise price of $0.21 per share were exercised and the Company received proceeds of $1,638,748 from exercise of these warrants. These warrants were issued during the year ended January 1, 2011 pursuant to a subscription agreement entered into by the holders of such warrants and the Company on April 22, 2010.
	During the year ended December 28, 2013, the warrants awarded to a certain non-employee during the year ended December 29, 2012 with an exercise price of $0.75 per share were exercised and the Company issued 74,186 shares of common stock.  The non-employee who held these warrants elected a cashless exercise pursuant to the provisions of the warrants and received 74,186 shares of common stock in lieu of 250,000 shares for a cash payment of $0.75 per share.
	During the year ended December 28, 2013, the warrants issued to Aegis Capital Corp. and its designees during the year ended December 29, 2012 with an exercise price of $0.85 per share were exercised and the Company issued 101,477 shares of common stock.  The warrant holders elected a cashless exercise pursuant to the provisions of the warrants and received 101,477 shares of common stock in lieu of 285,000 shares and a cash payment of $0.85 per share.
	During the year ended December 29, 2012, 750,000 warrants with an exercise price of $0.21 per share were exercised and the Company received proceeds of $157,500 from exercise of these warrants.  These warrants were issued during the year ended January 1, 2011 pursuant to a subscription agreement entered into by the holders of such warrants and the Company on April 22, 2010.
	During the year ended December 29, 2012, a part of the warrants issued to Aegis Capital Corp. and its designees, warrants with an exercise price of $0.85 per share were exercised and the Company issued 4,103 shares of common stock.  The warrant holder elected a cashless exercise pursuant to the provisions of the warrants and received 4,103 shares of common stock in lieu of 15,000 shares and a cash payment of $0.85 per share.  These warrants were issued during the year ended December 29, 2012 as part of Aegis Capital Corp.’s services as a placement agent in conjunction with the registered direct offering concluded during the year ended December 29, 2012.
	During the year ended December 29, 2012, the Company awarded warrants to purchase 250,000 shares of the Company’s common stock to a certain non-employee.  The exercise price of these warrants was $0.75 per share and the term for these warrants was 2 years.

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 28, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Note 13. Commitments and Contingencies	'
	Lease
	The Company leases its office and research facilities in California, Colorado and Maryland under operating lease agreements that expire at various dates from August 2014 through September 2019. Monthly lease payments range from $1,214 per month to $22,124 per month, and minimum lease payments escalate during the terms of the leases. Generally accepted accounting principles require total minimum lease payments to be recognized as rent expense on a straight-line basis over the term of the lease. The excess of such expense over amounts required to be paid under the lease agreement is carried as a liability on the Company’s consolidated balance sheet.
	Minimum future rental payments under all of the leases are as follows:
	Fiscal years ending:
	2014	$	524,000
	2015		515,000
	2016		319,000
	2017		225,000
	2018		233,000
		$	1,816,000
	Rent expense was approximately $519,000, and $512,000 for the years ended December 28, 2013 and December 29, 2012, respectively.
	Royalty
	The Company has 8 royalty agreements related to certain products the Company offers to its customers.  These agreements expire at various dates from December 31, 2019 through April 12, 2032.  Yearly minimum royalty payments including license maintenance fees range from $1,000 per year to $35,000 per year, however, these minimum payments escalate each year with a maximum of $50,000 per year.  In addition, the Company is required to pay a range of 2% to 5% of sales related to the licensed products under these agreements.  Total royalty expense including license maintenance fees from continuing operations for the year ended December 28, 2013 and December 29, 2012 was approximately $111,000 and $75,000, respectively under these agreements.  Minimum royalties including license maintenance fees for the next five years are as follows:
	Fiscal years ending:
	2014	$	150,000
	2015		179,000
	2016		199,000
	2017		201,000
	2018		200,000
		$	929,000
	Legal proceedings
	The Company from time to time is involved in legal proceedings in the ordinary course of our business, which can include employment claims, product claim, patent infringements, etc. We do not believe that any of these claims and proceedings against us as they arise are likely to have, individually or in the aggregate, a material adverse effect on our financial condition or results of operations.
	Severance payments to executive officers
	As of December 28, 2013, the Company has two executive officers, Frank Jaksch, Jr., Chief Executive Officer and Thomas Varvaro, Chief Financial Officer.  Upon termination, Mr. Jaksch and Mr. Varvaro will receive severance payments per the terms of the respective employment agreements entered with the Company.  The key terms of the employment agreements, including the severance terms are as follows:
	Employment Agreement with Frank L. Jaksch Jr.
	On April 19, 2010, the Company entered into an Amended and Restated Employment Agreement (the “Amended Jaksch Agreement”) with Frank L. Jaksch Jr. The Amended Jaksch Agreement has a three year term, beginning on the date of the Agreement, that automatically renews unless the Amended Jaksch Agreement is terminated in accordance with its terms. On January 2, 2014, the Board approved the recommendations of the Company’s Compensation Committee raising the annual base salary of Mr. Jaksch to $275,000 per year and raising the annual cash bonus target for Mr. Jaksch up to 50% of his base salary.
	The severance terms of the Amended Jaksch Agreement provide that in the event Mr. Jaksch’s employment with the Company is terminated voluntarily by Mr. Jaksch, he will be entitled to any accrued but unpaid base salary, any stock vested through the date of his termination and a pro-rated portion of 50% of his salary (50% of his salary being the “Maximum Annual Bonus”) for the year of termination. In addition, if Mr. Jaksch leaves the Company for “Good Reason”, (as defined in the Amended Jaksch Agreement), he will also be entitled to severance equal to the Maximum Annual Bonus, and he will be deemed to have been employed for the entirety of such year. Severance will then consist of 16 weeks of paid salary, unless Mr. Jaksch signs a release, in which case he will receive compensation equal to the lesser of the remainder of the term of the agreement, or up to 12 months paid salary.
	In the event that Mr. Jaksch is terminated by the Company for “Cause” (as defined in the Amended Jaksch Agreement), he will only be entitled to his accrued but unpaid base salary, and any stock vested through the date of his termination.
	In the event that Mr. Jaksch is terminated due to “Cessation of Business” (as defined in the Amended Jaksch Agreement), Mr. Jaksch will be entitled to a lump sum payment of base salary and an amount equal to the Maximum Annual Bonus, and continuation of health benefits until the earlier of the last to occur of the term or renewal term of the agreement or 12 months from the date of termination.
	In the event the Company terminates Mr. Jaksch’s employment “without Cause” (as defined in the Amended Jaksch Agreement), Mr. Jaksch will be entitled to severance in the form of any stock vested through the date of his termination and continuation of his base salary for a period of eight weeks, or, if Mr. Jaksch enters into a standard separation agreement, Mr. Jaksch will receive continuation of base salary and health benefits, together with applicable fringe benefits as provided to other executive employees until the last to occur of the expiration of the term or renewal term then in effect or 24 months from the date of termination (the “Severance Period”), and he will receive his Maximum Annual Bonus if the Severance Period is equal to 24 months or a pro rata portion thereof if less, as well as the full vesting of any otherwise unvested stock.
	Employment Agreement with Thomas C. Varvaro
	On April 19, 2010, the Company entered into an Amended and Restated Employment Agreement (the “Amended Varvaro Agreement”) with Thomas C. Varvaro. The Amended Varvaro Agreement has a three year term beginning on the date of the agreement that automatically renews unless the Amended Varvaro Agreement is terminated in accordance with its terms. On January 2, 2014, the Board approved the recommendations of the Company’s Compensation Committee raising the annual base salary of Mr. Varvaro to $225,000 per year and raising the annual cash bonus target for Mr. Varvaro up to 40% of his base salary.
	The severance terms of the Amended Varvaro Agreement provide that in the event Mr. Varvaro’s employment with us is terminated voluntarily by Mr. Varvaro he will be entitled to any accrued but unpaid base salary, any stock vested through the date of his termination and a pro-rated portion of 40% of his salary (40% of this salary being the “Maximum Annual Bonus”) for the year of termination. In addition, if Mr. Varvaro leaves the Company for “Good Reason” (as defined in the Amended Varvaro Agreement), he will also be entitled to severance equal to the Maximum Annual Bonus, and he shall be deemed to have been employed for the entirety of such year. Severance will then consist of 16 weeks of paid salary, unless Mr. Varvaro signs a release, in which case he will receive compensation equal to the lesser of the remainder of his agreement or 12 months paid salary.
	In the event that Mr. Varvaro is terminated by the Company for “Cause” (as defined in the Amended Varvaro Agreement), he will only be entitled to his accrued but unpaid base salary, and any stock vested through the date of his termination.
	In the event that Mr. Varvaro is terminated due to a “Cessation of Business” (as defined in the Amended Varvaro Agreement), Mr. Varvaro will be entitled to a lump sum payment of base salary and an amount equal to the Maximum Annual Bonus, and continuation of health benefits until the last to occur of the term or renewal term of the agreement or 12 months from the date of termination.
	In the event the Company terminates Mr. Varvaro’s employment “without Cause,” Mr. Varvaro will be entitled to severance in the form of any stock vested through the date of his termination and continuation of his base salary for a period of eight weeks, or, if Mr. Varvaro enters into a standard separation agreement, Mr. Varvaro will receive continuation of base salary and health benefits, together with applicable fringe benefits as provided to other executive employees until the last to occur of the expiration of the term or renewal term then in effect or 24 months from the date of termination (the “Severance Period”), will receive his Maximum Annual Bonus if the Severance Period is equal to 24 months or a pro rata portion thereof if less, as well as the full vesting of any otherwise unvested stock.

Business_Segmentation_and_Geog

Business Segmentation and Geographical Distribution	12 Months Ended
	Dec. 28, 2013
Business Segmentation And Geographical Distribution	'
Note 14. Business Segmentation and Geographical Distribution	'
	Since the year ended December 29, 2012, the Company began segregating its financial results for Spherix Consulting, Inc. (“Spherix”), which the Company acquired on December 3, 2012.  Spherix provides scientific and regulatory consulting.  The Company has following three reportable segments.
		•	Core standards, contract services and ingredients segment includes supply of phytochemical reference standards, which are small quantities of plant-based compounds typically used to research an array of potential attributes, and reference materials, related contract services, and proprietary ingredients.
		•	Scientific and regulatory consulting segment which consist of providing scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage potential health and regulatory risks.
		•	Retail dietary supplement products segment which consist of the supply of the BluScience line of dietary supplement products containing the Company's proprietary ingredients to various retail distribution channels.  On March 28, 2013, the Company entered into an asset sale agreement with NeutriSci and consummated the sale of BluScience consumer product line to NeutriSci.
	The “Other” classification includes corporate items not allocated by the Company to each reportable segment. Further, there are no intersegment sales that require elimination.  The Company evaluates performance and allocates resources based on reviewing gross margin by reportable segment.
			Core Standards,		Scientific and		Retail
			Contract Services and		Regulatory		Dietary Supplement
	Year ended		Ingredients segment		Consulting segment		Products segment			Other			Total
	28-Dec-13
	Net sales		$	9,074,531	$	1,146,718	$	(60,285	)	$	-		$	10,160,964
	Cost of sales			6,394,836		632,037		955			-			7,027,828
	Gross profit (loss)			2,679,695		514,681		(61,240	)		-			3,133,136
	Operating expenses:
	Sales and marketing			2,211,741		14,705		131,159			-			2,357,605
	General and administrative			-		-		-			5,117,016			5,117,016
	Loss from investment in affiliate			-		-		-			44,961			44,961
	Operating expenses			2,211,741		14,705		131,159			5,161,977			7,519,582
	Operating income (loss)		$	467,954	$	499,976	$	(192,399	)	$	(5,161,977	)	$	(4,386,446	)
			Core Standards,		Scientific and		Retail
			Contract Services and		Regulatory		Dietary Supplement
	Year ended		Ingredients segment		Consulting segment		Products segment			Other			Total
	29-Dec-12
	Net sales		$	8,458,082	$	69,718	$	3,082,694		$	-		$	11,610,494
	Cost of sales			6,075,050		25,729		3,234,278			-			9,335,057
	Gross profit (loss)			2,383,032		43,989		(151,584	)		-			2,275,437
	Operating expenses:
	Sales and marketing			2,227,934		-		3,292,207			-			5,520,141
	General and administrative			-		-		-			8,391,730			8,391,730
	Operating expenses			2,227,934		-		3,292,207			8,391,730			13,911,871
	Operating income (loss)		$	155,098	$	43,989	$	(3,443,791	)	$	(8,391,730	)	$	(11,636,434	)
			Core Standards,		Scientific and		Retail
			Contract Services and		Regulatory		Dietary Supplement
	At December 28, 2013		Ingredients segment		Consulting segment		Products segment			Other			Total
	Total assets		$	4,036,126	$	139,765	$	-		$	4,811,001		$	8,986,892
			Core Standards,		Scientific and		Retail
			Contract Services and		Regulatory		Dietary Supplement
	At December 29, 2012		Ingredients segment		Consulting segment		Products segment			Other			Total
	Total assets		$	3,542,355	$	72,573	$	4,331,866		$	1,087,727		$	9,034,521
	Revenue from international sources for the core standards, contract services and ingredients segment approximated $1,510,000 and $1,690,000 for the years ended December 28, 2013 and December 29, 2012, respectively.  Revenues from international sources for the scientific and regulatory consulting segment approximated $450,000 and $4,000 for the years ended December 28, 2013 and December 29, 2012, respectively.  International sources which the Company generates revenue include Europe, North America, South America, Asia, and Oceania.  We did not have any revenue from international sources for the retail dietary supplement products segment for the years ended December 28, 2013 and December 29, 2012.
	The Company’s long-lived assets are located within the United States.

RelatedParty_Transactions

Related-Party Transactions	12 Months Ended
	Dec. 28, 2013
Related Transactions	'
Note 15. Related Party Transactions	'
	On February 9, 2012, the Company and Opko Health, Inc. (“OPKO”) entered into a license, supply and distribution agreement.  Pursuant to this agreement, the Company has licensed to OPKO certain new product offerings and health care technologies for distribution and business development throughout Latin America.  As of December 28, 2013, there were no transactions between the Company and OPKO under this agreement, but the initial product to be commercialized is our proprietary product pterostilbene.  On July 10, 2012, the Company and OPKO entered into another agreement, pursuant to which OPKO was retained to serve as management consultant and advisor to the Company.  That agreement expired on October 10, 2012. As a consideration for the services, the Company granted OPKO 500,000 shares of its common stock.  The fair value of this stock award was $320,000 and was measured using the Company’s stock price on the date of award.  The expense was amortized over the three month period which the services had been provided.  Dr. Phillip Frost, who beneficially owns 15,252,937 shares of the Company’s common stock, or 14.5% of the Company’s outstanding shares as of December 28, 2013, is Chairman of the Board and Chief Executive Officer of OPKO.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 28, 2013
Subsequent Events [Abstract]	'
Note 16. Subsequent Events	'
	Subsequent to the year ended December 28, 2013, the Company assigned a senior convertible secured note issued by NeutriSci to an unrelated third party.  At the date of assignment, $2,275,000 remained outstanding on the senior secured convertible note.  The transaction amount was for $1,250,000 and the Company received net proceeds of $1,092,500 after deducting transaction costs of $150,000 cash fee paid to a placement agent, Palladium Capital Advisors, LLC, and $7,500 legal fee.  There is no recourse provision to the Company associated with the assignment of the note.  The Company also agreed to transfer a number of shares of preferred stock of NeutriSci having a value of $500,000 to an unrelated third party and $50,000 to Palladium at a later date.
	On January 2, 2014, the Company awarded 1,090,000 shares of the Company’s restricted stock, subject to certain vesting provisions to the Company’s officers and the members of the board of directors.

Significant_Accounting_Policie1

Significant Accounting Policies (Policy)	12 Months Ended
	Dec. 28, 2013
Accounting Policies [Abstract]	'
Basis of presentation	'
	Basis of presentation:  The financial statements and accompanying notes have been prepared on a consolidated basis and reflect the consolidated financial position of the Company and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated from these financial statements. The Company’s fiscal year ends on the Saturday closest to December 31.  The fiscal years ended December 28, 2013 (referred to as 2013), and December 29, 2012 (referred to as 2012), each consisted of 52 weeks. Every fifth or sixth fiscal year, the inclusion of an extra week occurs due to the Company’s floating year-end date. The fiscal year 2014 will include 53 weeks instead of the normal 52 weeks.
Accounting estimates	'
	Accounting estimates:  The preparation of financial statements requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.
Revenue recognition	'
	Revenue recognition:  The Company recognizes sales and the related cost of sales at the time the merchandise is shipped to customers or service is performed, when each of the following conditions have been met:  an arrangement exists, delivery has occurred, there is a fixed price, and collectability is reasonably assured.  Discounts, returns and allowances related to sales, including an estimated reserve for the returns and allowances, are recorded as reduction of revenue.
	Shipping and handling fees billed to customers and the cost of shipping and handling fees billed to customers are included in net sales.  For the year ending in December 28, 2013, shipping and handling fees billed to customers were approximately $110,000 and the cost of shipping and handling fees billed to customers was approximately $128,400.  For the year ending in December 29, 2012, shipping and handling fees billed to customers were approximately $109,000 and the cost of shipping and handling fees billed to customers was approximately $123,000.  Shipping and handling fees not billed to customers are recognized as cost of sales.
	Taxes collected from customers and remitted to governmental authorities are excluded from revenue, which is presented on a net basis in the statement of operations.
Cash concentration	'
	Cash concentration:  The Company maintains substantially all of its cash in one bank account.
Trade accounts receivable	'
	Trade accounts receivable:  Trade accounts receivable are carried at original invoice amount less an estimate made for doubtful receivables based on monthly and quarterly reviews of all outstanding amounts.  Management determines the allowance for doubtful accounts by identifying troubled accounts and by using historical experience applied to an aging of accounts.  $433,000 of the allowance amount for the period ended December 29, 2012 represents a hold on the receivables placed by a retailer that carried our BluScience retail consumer product line.  The hold was placed by the retailer as an offset in the event of future returns of the Company’s products and the hold was treated as a reduction of revenue. On March 28, 2013, the Company sold the BluScience retail consumer line to NeutriSci and the related trade accounts receivable including the allowance have been transferred to NeutriSci.  Trade accounts receivable are written off when deemed uncollectible.  Recoveries of trade accounts receivable previously written off are recorded when received.
Other receivables	'
	Other receivables:  Other receivables are amounts due for payment to the Company other than the Company’s normal customer invoices for merchandise shipped or services performed.  The other receivable amount was from a legal settlement agreement, which the settlement was reached at arbitration form a lawsuit for the violation of the Company’s trademarks.  The counterparty had already remitted the payment to a third party escrow agent prior to December 28, 2013.  This payment was deposited by the Company on January 14, 2014.  The other receivable amount was recorded as a gain in general and administrative expenses in the statement of operations for the period ended December 28, 2013.
Inventories	'
	Inventories:  Inventories are comprised of raw materials, work-in-process and finished goods.  They are stated at the lower of cost, determined by the first-in, first-out method (FIFO) method, or market.  The inventory on the balance sheet is recorded net of valuation allowances.  Labor and overhead has been added to inventory that was manufactured or characterized by the Company.  The amounts of major classes of inventory for the periods ended December 28, 2013 and December 29, 2012 are as follows:
			2013		2012
	Reference standards		$	1,769,160	$	1,614,755
	Bulk ingredients			694,965		432,230
	Dietary supplements – raw materials			-		401,809
	Dietary supplements – work in process			-		465,253
	Dietary supplements – finished goods			-		2,657,257
				2,464,125		5,571,304
	Less valuation allowance			260,000		366,000
			$	2,204,125	$	5,205,304
	The Company regularly reviews inventories on hand and records a provision for slow-moving and obsolete inventory, inventory not meeting quality standards and inventory subject to expiration. The provision for slow-moving and obsolete inventory is based on current estimates of future product demand, market conditions and related management judgment. Any significant unanticipated changes in future product demand or market conditions that vary from current expectations could have an impact on the value of inventories.
Intangible assets	'
	Intangible assets:  Intangible assets include licensing rights and are accounted for based on the fair value of consideration given or the fair value of the net assets acquired, whichever is more reliable. Intangible assets with finite useful lives are amortized using the straight-line method over a period of 10 years, or, for licensed patent rights, the remaining term of the patents underlying licensing rights (considered to be the remaining useful life of the license).
Leasehold improvements and equipment	'
	Leasehold improvements and equipment:  Leasehold improvements and equipment are carried at cost and depreciated on the straight-line method over the lesser of the estimated useful life of each asset or lease term. Leasehold improvements and equipment are comprised of leasehold improvements, laboratory equipment, furniture and fixtures, and computer equipment. Depreciation on equipment under capital lease is included with depreciation on owned assets.  The costs incurred for a routine maintenance to keep the asset operating at its present condition are expensed.  Useful lives of leasehold improvements and equipment for each of the category are as follows:
		Useful Life
	Leasehold improvements	Until the end of the lease term
	Computer equipment	3 to 5 years
	Furniture and fixtures	7 years
	Laboratory equipment	10 years
	Long-lived assets are reviewed for impairment on a periodic basis and when changes in circumstances indicate the possibility that the carrying amount may not be recoverable.  Long-lived assets are grouped at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets.  If the forecast of undiscounted future cash flows is less than the carrying amount of the assets, an impairment charge would be recognized to reduce the carrying value of the assets to fair value.  If a possible impairment is identified, the asset group’s fair value is measured relying primarily on a discounted cash flow methodology.
Long-term investment in affiliate	'
	Long-term investment in affiliate: The Company accounts for its investment in affiliate under the equity method.  The Company records equity method adjustments in gains (losses) on equity method investments, net, and may do so with up to a three-month lag, pending on the timely availability of financial information of the investee.  Equity method adjustments include: our proportionate share of investee income or loss, gains or losses resulting from investee capital transactions, and other adjustments required by the equity method.  The long-term investment in affiliate is subject to a periodic impairment review and is considered to be impaired when a decline in carrying value is judged to be other-than-temporary.  Evidence of a loss in value might include (i) absence of an ability recover the carrying amount of the investment or (ii) inability of the investee to sustain an earnings capacity that would justify the carrying amount of the investment.
Customer deposits and other	'
	Customer deposits and other:  Customer deposits and other represent either (i) cash received from customers in advance of product shipment or delivery of services; or (ii) cash received from government as research grants, which the Company has yet to complete the research activities.
	The cash received from government as research grants is recognized as a liability until the research is performed.  Other than a nominal management fee, which the Company is entitled to earn when the research is performed, the research activities related to the grants are excluded from revenue and are presented on a net basis in the statement of operations.
Income taxes	'
	Income taxes:  Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards and deferred liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.
	The Company has not recorded a reserve for any tax positions for which the ultimate deductibility is highly certain but for which there is uncertainty about the timing of such deductibility. The Company files tax returns in all appropriate jurisdictions, which include a federal tax return and various state tax returns. Open tax years for these jurisdictions are 2010 to 2013, which statutes expire in 2014 to 2016, respectively. When and if applicable, potential interest and penalty costs are accrued as incurred, with expenses recognized in general and administrative expenses in the statements of operations. As of December 28, 2013, the Company has no liability for unrecognized tax benefits.
Research and development costs	'
	Research and development costs:  Research and development costs consist of direct and indirect costs associated with the development of the Company’s technologies. These costs are expensed as incurred.  Research and development costs for the periods ended December 28, 2013 and December 29, 2012 were approximately $134,000 and $142,000, respectively.
Advertising	'
	Advertising: The Company expenses the production costs of advertising the first time the advertising takes place.   Advertising expense for the periods ended December 28, 2013 and December 29, 2012 were approximately $355,000 and $2,565,000, respectively.
Share-based compensation	'
	Share-based compensation:  The Company has an Equity Incentive Plan under which the Board of Directors may grant restricted stock or stock options to employees and non-employees.  For employees, share-based compensation cost is recorded for all option grants and awards of non-vested stock based on the grant date fair value of the award, and is recognized over the period the employee is required to provide services for the award.  For non-employees, share-based compensation cost is recorded for all option grants and awards of non-vested stock and is remeasured over the vesting term as earned.  The expense is recognized over the period the non-employee is required to provide services for the award.
	The Company recognizes compensation expense over the requisite service period using the straight-line method for option grants without performance conditions.  For stock options that have both service and performance conditions, the Company recognizes compensation expense using the graded attribution method.  Compensation expense for stock options with performance conditions is recognized only for those awards expected to vest.
	From time to time, the Company awards shares of its common stock to non-employees for services provided or to be provided.  If the fair value of services received is more reliably measurable than the fair value of the stock awarded, the fair value of the services received is used to measure the award.  In contrast, if the fair value of the stock issued is more reliably measurable, than the fair value of services received, the award is measured based on the fair value of the stock awarded.  Since these stock awards are fully vested and non-forfeitable, upon issuance the measurement date for the award is usually reached on the date of the award.  The measured fair value of the award is amortized over the period the service is provided.
Fair Value Measurement	'
	Fair Value Measurement: The Company follows the provisions of the accounting standard which defines fair value, establishes a framework for measuring fair value and enhances fair value measurement disclosure. Under these provisions, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.
	The standard establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use on unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is described below:
	Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.
	Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data.
	Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.
Financial instruments	'
	Financial instruments:  The carrying amounts reported in the balance sheet for accounts receivable and accounts payable approximate their fair values.  The carrying amounts reported in the balance sheet for capital lease obligations are present values of the obligations, excluding the interest portion.  Capital lease obligations with maturities less than one year are classified as current liabilities.

Significant_Accounting_Policie2

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 28, 2013
Accounting Policies [Abstract]	'
Inventories	'
	The amounts of major classes of inventory for the periods ended December 28, 2013 and December 29, 2012 are as follows:
			2013		2012
	Reference standards		$	1,769,160	$	1,614,755
	Bulk ingredients			694,965		432,230
	Dietary supplements – raw materials			-		401,809
	Dietary supplements – work in process			-		465,253
	Dietary supplements – finished goods			-		2,657,257
				2,464,125		5,571,304
	Less valuation allowance			260,000		366,000
			$	2,204,125	$	5,205,304
Leasehold improvements and equipment	'
	Useful lives of leasehold improvements and equipment for each of the category are as follows:
		Useful Life
	Leasehold improvements	Until the end of the lease term
	Computer equipment	3 to 5 years
	Furniture and fixtures	7 years
	Laboratory equipment	10 years

Earnings_Per_Share_Tables

Earnings Per Share (Tables)	12 Months Ended
	Dec. 28, 2013
Earnings Per Share Tables	'
Earnings Per Share	'
		Years Ended
		2013		2012
	Basic weighted average common shares outstanding		99,987,443		90,268,802
	Warrants and options in the money, net		605,567		5,720,320
	Weighted average common shares outstanding assuming dilution		100,593,010		95,989,122

Sale_of_Product_Line_and_Inves1

Sale of Product Line and Investment in Affiliate (Tables)	12 Months Ended
	Dec. 28, 2013
Sale Of Product Line And Investment In Affiliate	'
Carrying value determination	'
		At March 28, 2013
	Assets transferred
	Trade receivables, less allowance for returns	$	(16,984	)
	Inventories		3,467,530
	Prepaid expenses and other assets		76,131
	Total assets transferred		3,526,677
	Liabilities transferred
	Accounts payable		368,873
	Total liabilities transferred		368,873
	Total net assets transferred	$	3,157,804
	Initial monetary consideration received
	Cash	$	500,000
	Non-trade receivable		500,000
	Total initial monetary consideration received	$	1,000,000
	Carrying Value of Long Term Investment in Affiliate	$	2,157,804
NeutriSci Business information	'
		30-Sep-13
	Sales	$	36,451
	Gross profit		13,310
	Net loss	$	(813,212	)
Change in Carrying Value and Ownership	'
	Changes in Carrying Value and Ownership Percentage for ChromaDex Corporation
		Carrying Value			Ownership
					Percentage
	At March 28, 2013	$	2,157,804			5.7	%
	Company's share of NeutriSci's loss through September 30, 2013		(44,961	)		-
	Proceeds from investment in affiliate		(225,000	)		-
	At December 28, 2013	$	1,887,844			4.9	%

Intangible_Assets_Tables

Intangible Assets (Tables)	12 Months Ended
	Dec. 28, 2013
Intangible Assets Tables	'
Intangible assets	'
			2013					2012
			Gross Carrying			Accumulated		Gross Carrying		Accumulated
			Amount			Amortization		Amount		Amortization
	Amortized intangible assets:
	License agreements and other	$	1,075,285		$	873,635	$	986,285	$	850,103
Estimated aggregate amortization expense	'
	Estimated aggregate amortization expense for each of the next five years is as follows:
	Years ending December:
	2014		$	28,000
	2015			28,000
	2016			28,000
	2017			28,000
	2018			23,000
	Thereafter			67,000
			$	202,000

Leasehold_Improvements_and_Equ1

Leasehold Improvements and Equipment (Tables)	12 Months Ended
	Dec. 28, 2013
Leasehold Improvements And Equipment	'
Leasehold Improvements and Equipment	'
	Leasehold improvements and equipment consisted of the following:
		2013		2012
	Laboratory equipment	$	2,782,364	$	2,439,688
	Leasehold improvements		491,125		403,971
	Computer equipment		372,851		363,739
	Furniture and fixtures		18,313		18,313
	Office equipment		7,877		7,877
	Construction in progress		40,126		106,080
			3,712,656		3,339,668
	Less accumulated depreciation		2,649,417		2,403,242
		$	1,063,239	$	936,426

Capitalized_Lease_Obligations_

Capitalized Lease Obligations (Tables)	12 Months Ended
	Dec. 28, 2013
Capitalized Lease Obligations Tables	'
Minimum future lease payments	'
	Minimum future lease payments under capital leases as of December 28, 2013, are as follows:
	Year ending December:
	2014	$	172,948
	2015		112,794
	2016		99,902
	2017		79,054
	2018		30,198
	Total minimum lease payments		494,896
	Less amount representing interest at a rate of approximately 9.8% per year		75,667
	Present value of net minimum lease payments		419,229
	Less current portion		138,887
	Long-term obligations under capital leases	$	280,342

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
	Dec. 28, 2013
Income Taxes Tables	'
Reconciliation of income tax expense (benefit)	'
	A reconciliation of income tax expense (benefit) computed at the statutory federal income tax rate of 34% for 2013 and 2012 compared to the Company’s income tax expense for the years ended December 28, 2013 and December 29, 2012 is as follows:
		2013			2012
	Income tax expense (benefit) at statutory rate	$	(1,503,000	)	$	(3,965,000	)
	(Increase) decrease resulting from:
	State income taxes, net of federal tax effect		(189,000	)		(428,000	)
	Nondeductible expenses		117,000			134,000
	Change in effective tax rate		(166,000	)		194,000
	Change in valuation allowance		1,732,000			4,136,000
	Other		9,000			(71,000	)
		$	-		$	-
Deferred income tax assets and liabilities	'
	The deferred income tax assets and liabilities consisted of the following components as of December 28, 2013 and December 29, 2012:
		2013			2012
	Deferred tax assets:
	Net operating loss carryforward	$	8,953,000		$	8,512,000
	Stock options and restricted stock		1,945,000			1,679,000
	Investment in affiliate related to BluScience transaction		1,187,000			-
	Inventory reserve		100,000			138,000
	Allowance for doubtful accounts		3,000			169,000
	Accrued expenses		164,000			134,000
	Intangibles		36,000			48,000
	Deferred rent		99,000			76,000
			12,487,000			10,756,000
	Less valuation allowance		12,361,000			10,629,000
			126,000			127,000
	Deferred tax liabilities:
	Leasehold improvements and equipment		(100,000	)		(101,000	)
	Prepaid expenses		(26,000	)		(26,000	)
			(126,000	)		(127,000	)
		$	-		$	-

Employee_Equity_Incentive_Plan1

Employee Equity Incentive Plan (Tables)	12 Months Ended
	Dec. 28, 2013
Employee Equity Incentive Plan Tables	'
Weighted average assumptions of stock options granted	'
	Year Ended December	2013			2012
	Volatility		32.75	%		33.22	%
	Expected dividends		0	%		0	%
	Expected term	6.0 years			5.8 years
	Risk-free rate		1.51	%		0.96	%
Service Period Based Stock Options	'
	The following table summarizes service period based stock options activity at December 28, 2013 and changes during the year then ended:
					Weighted Average
								Remaining		Aggregate
		Number of			Exercise			Contractual		Intrinsic
		Shares			Price			Term		Value
	Outstanding at December 29, 2012		12,202,558		$	1.08
	Options Granted		805,000			0.81
	Options Exercised		(26,038	)		0.51
	Options Expired		(75,000	)		0.5
	Options Forfeited		(792,865	)		1.19
	Outstanding at December 28, 2013		12,113,655		$	1.06			7.43	$	6,513,219
	Exercisable at December 28, 2013		8,184,312		$	1.14			6.76	$	3,767,235
Performance Based Stock Options	'
	The following table summarizes performance based stock options activity at December 28, 2013 and changes during the year then ended:
					Weighted Average
								Remaining		Aggregate
		Number of			Exercise			Contractual		Intrinsic
		Shares			Price			Term		Value
	Outstanding at December 29, 2012		145,834		$	1.59
	Options Granted		200,000			0.63
	Options Exercised		-			-
	Options Expired		-			-
	Options Forfeited		(145,834	)		1.59
	Outstanding at December 28, 2013		200,000		$	0.63			9.08	$	194,000
	Exercisable at December 28, 2013		-		$	-			-	$	-
Restricted stock awards granted to employees	'
	The following table summarizes activity of restricted stock awards granted to employees at December 28, 2013 and changes during the twelve months then ended:
					Weighted Average
					Award-Date
		Shares			Fair Value
	Unvested shares at December 29, 2012		500,000		$	0.69
	Granted		-			-
	Vested		-			-
	Forfeited		-			-
	Unvested shares at December 28, 2013		500,000		$	0.69
	Expected to Vest as of December 28, 2013		500,000		$	0.69
Weighted average assumptions of restricted stock	'
	The table below outlines the weighted average assumptions of these market conditioned restricted stock awarded to employees during the year ended December 29, 2012.
	Year Ended December 29, 2012	2012
	Expected Term		3
	Expected Volatility		69.98	%
	Expected Dividends		0	%
	Risk Free Rate of Return		0.39	%

NonEmployee_ShareBased_Compens1

Non-Employee Share-Based Compensation (Tables)	12 Months Ended
	Dec. 28, 2013
Non-Employee Share-Based Compensation Tables	'
Non-Employee stock options	'
	The following table summarizes activity of stock options granted to non-employees at December 28, 2013 and changes during the year then ended:
					Weighted Average
							Remaining		Aggregate
		Number of			Exercise		Contractual		Intrinsic
		Shares			Price		Term		Value
	Outstanding at December 29, 2012		1,097,300		$	1.23
	Options Granted		-			-
	Options Exercised		(250,000	)		0.5
	Options Forfeited		-			-
	Outstanding at December 28, 2013		847,300		$	1.44		5.74	$	131,627
	Exercisable at December 28, 2013		847,300		$	1.44		5.74	$	131,627
Warrant award assumptions	'
	The fair value of these warrants was estimated at the date of award using the Black-Scholes based valuation model.  The table below outlines the assumptions for the warrants granted.
	Year Ended December 29, 2012	2012
	Volatility		28.2	%
	Expected dividends		0	%
	Expected term	2.0 years
	Risk-free rate		0.27	%

Stock_Issuance_Tables

Stock Issuance (Tables)	12 Months Ended
	Dec. 28, 2013
Stock Issuance Tables	'
Aegies Capital Corp. warrant assumptions	'
	Year Ended December 29, 2012	2012
	Volatility		29.7	%
	Expected dividends		0	%
	Expected term	2.5 years
	Risk-free rate		0.28	%

Warrants_Tables

Warrants (Tables)	12 Months Ended
	Dec. 28, 2013
Warrants Tables	'
Warrants	'
					Weighted Average
							Remaining		Aggregate
		Number of			Exercise		Contractual		Intrinsic
		Shares			Price		Term		Value
	Outstanding at December 29, 2012		10,056,914		$	0.72
	Warrants Granted		-			-
	Warrants Exercised		(8,338,564	)		0.25
	Warrants Expired		(1,718,350	)		3
	Outstanding at December 28, 2013		-		$	-		-	$	-
	Exercisable at December 28, 2013		-		$	-		-	$	-

Commitments_and_Contingencis_T

Commitments and Contingencis (Tables)	12 Months Ended
	Dec. 28, 2013
Commitments Tables	'
Minimum future rental payments	'
	Minimum future rental payments under all of the leases are as follows:
	Fiscal years ending:
	2014	$	524,000
	2015		515,000
	2016		319,000
	2017		225,000
	2018		233,000
		$	1,816,000
Minimum royalties including license maintenance fees	'
	Minimum royalties including license maintenance fees for the next five years are as follows:
	Fiscal years ending:
	2014	$	150,000
	2015		179,000
	2016		199,000
	2017		201,000
	2018		200,000
		$	929,000

Business_Segmentation_and_Geog1

Business Segmentation and Geographical Distribution (Tables)	12 Months Ended
	Dec. 28, 2013
Business Segmentation And Geographical Distribution Tables	'
Business Segmentation and Geographical Distribution	'
		Core Standards,		Scientific and		Retail
		Contract Services and		Regulatory		Dietary Supplement
	Year ended	Ingredients segment		Consulting segment		Products segment			Other			Total
	28-Dec-13
	Net sales	$	9,074,531	$	1,146,718	$	(60,285	)	$	-		$	10,160,964
	Cost of sales		6,394,836		632,037		955			-			7,027,828
	Gross profit (loss)		2,679,695		514,681		(61,240	)		-			3,133,136
	Operating expenses:
	Sales and marketing		2,211,741		14,705		131,159			-			2,357,605
	General and administrative		-		-		-			5,117,016			5,117,016
	Loss from investment in affiliate		-		-		-			44,961			44,961
	Operating expenses		2,211,741		14,705		131,159			5,161,977			7,519,582
	Operating income (loss)	$	467,954	$	499,976	$	(192,399	)	$	(5,161,977	)	$	(4,386,446	)
		Core Standards,		Scientific and		Retail
		Contract Services and		Regulatory		Dietary Supplement
	Year ended	Ingredients segment		Consulting segment		Products segment			Other			Total
	29-Dec-12
	Net sales	$	8,458,082	$	69,718	$	3,082,694		$	-		$	11,610,494
	Cost of sales		6,075,050		25,729		3,234,278			-			9,335,057
	Gross profit (loss)		2,383,032		43,989		(151,584	)		-			2,275,437
	Operating expenses:
	Sales and marketing		2,227,934		-		3,292,207			-			5,520,141
	General and administrative		-		-		-			8,391,730			8,391,730
	Operating expenses		2,227,934		-		3,292,207			8,391,730			13,911,871
	Operating income (loss)	$	155,098	$	43,989	$	(3,443,791	)	$	(8,391,730	)	$	(11,636,434	)
		Core Standards,		Scientific and		Retail
		Contract Services and		Regulatory		Dietary Supplement
	At December 28, 2013	Ingredients segment		Consulting segment		Products segment			Other			Total
	Total assets	$	4,036,126	$	139,765	$	-		$	4,811,001		$	8,986,892
		Core Standards,		Scientific and		Retail
		Contract Services and		Regulatory		Dietary Supplement
	At December 29, 2012	Ingredients segment		Consulting segment		Products segment			Other			Total
	Total assets	$	3,542,355	$	72,573	$	4,331,866		$	1,087,727		$	9,034,521

Nature_of_Business_and_Liquidi1

Nature of Business and Liquidity (Details Narrative) (USD $)	3 Months Ended	12 Months Ended
	Mar. 26, 2014	Dec. 28, 2013	Dec. 29, 2012
Liquidity	'	'	'
Operating loss	'	($4,386,446)	($11,636,434)
Net loss	'	-4,419,525	-11,662,426
Cash and cash equivalents	'	2,261,336	520,000
Subsequent events	'	'	'
Outstanding balance of senior secured convertible note assigned to unrelated party	2,275,000	'	'
Transaction amount of note assignment	1,250,000	'	'
Net proceeds of note assignment	$1,092,500	'	'
NeutriSci preferred shares due at a later date	550,000	'	'

Significant_Accounting_Policie3

Significant Accounting Policies (Details) (USD $)	Dec. 28, 2013	Dec. 29, 2012
Inventories	'	'
Reference standards	$1,769,160	$1,614,755
Bulk ingredients	694,965	432,230
Dietary supplements - raw materials	'	401,809
Dietary supplements - work in process	'	465,253
Dietary supplements - finished goods	'	2,657,257
Inventory-gross	2,464,125	5,571,304
Less valuation allowance	260,000	366,000
Inventory-net	$2,204,125	$5,205,304

Significant_Accounting_Policie4

Significant Accounting Policies (Details 1)	12 Months Ended
	Dec. 28, 2013
Computer Equipment [Member] | Minimum [Member]	'
Useful life	'3 years
Computer Equipment [Member] | Maximum [Member]	'
Useful life	'5 years
Furniture and Fixtures [Member]	'
Useful life	'7 years
LaboratoryEquipment [Member]	'
Useful life	'10 years
Leaseholds and Leasehold Improvements [Member]	'
Useful life description	'Until the end of the lease term

Significant_Accounting_Policie5

Significant Accounting Policies (Details Narrative) (USD $)	12 Months Ended
	Dec. 28, 2013	Dec. 29, 2012
Accounting Policies [Abstract]	'	'
Shipping and handling fees billed	$110,000	$109,000
Cost of shipping and handling	128,400	123,000
Research and development costs	134,000	142,000
Advertising expense	355,000	2,565,000
Allowance for doubtful accounts	'	$433,000

Earnings_Per_Share_Details

Earnings Per Share (Details)	12 Months Ended
	Dec. 28, 2013	Dec. 29, 2012
Earnings per share	'	'
Basic weighted average common shares outstanding	99,987,443	90,268,802
Warrants and options in the money, net	605,567	5,720,320
Weighted average common shares outstanding assuming dilution	100,593,010	95,989,122

Earnings_Per_Share_Details_Nar

Earnings Per Share (Details Narrative)	Dec. 28, 2013	Dec. 29, 2012
Earnings Per Share Details Narrative	'	'
Warrants and options not in the money	145,000	14,914,696

Sale_of_Product_Line_and_Inves2

Sale of Product Line and Investment in Affiliate (Details) (USD $)	Mar. 28, 2013
Assets transferred	'
Trade receivables, less allowance for returns	($16,984)
Inventories	3,467,530
Prepaid expenses and other assets	76,131
Total assets transferred	3,526,677
Liabilities transferred	'
Accounts payable	368,873
Total liabilities transferred	368,873
Total net assets transferred	3,157,804
Initial Monetary Consideration received	'
Cash	500,000
Non-trade receivable	500,000
Total initial monetary consideration received	1,000,000
Carrying Value of Long Term Investment in Affiliate	$2,157,804

Sale_of_Product_Line_and_Inves3

Sale of Product Line and Investment in Affiliate (Details 1) (NeutriSci [Member], USD $)	6 Months Ended
	Sep. 28, 2013
NeutriSci [Member]	'
Sales	$36,451
Gross profit	13,310
Net loss	($813,212)

Sale_of_Product_Line_and_Inves4

Sale of Product Line and Investment in Affiliate (Details 2) (NeutriSci [Member], USD $)	6 Months Ended	9 Months Ended
	Sep. 28, 2013	Dec. 28, 2013	Dec. 29, 2012
NeutriSci [Member]	'	'	'
Carrying value, equity investment, beginning balance	$2,157,804	$2,157,804	$2,157,804
Company's share of NeutriSci's loss through September 30, 2013	-44,961	'	'
Proceeds from investment in affiliate	'	-225,000	'
Carrying value, equity investment, ending balance	'	$1,887,844	$2,157,804
Changes in Carrying Value and Ownership Percentage for ChromaDex Corporation	'	'	'
Ownership percentage, end of period	5.70%	4.90%	'

Sale_of_Product_Line_and_Inves5

Sale of Product Line and Investment in Affiliate (Details Narrative) (USD $)	3 Months Ended		12 Months Ended
	Mar. 26, 2014	Dec. 28, 2013	Dec. 28, 2013	Dec. 28, 2013	Mar. 30, 2013
			NeutriSci [Member]	NeutriSci [Member]	NeutriSci [Member]
Sale transaction value, cost recovery method	'	'	$3,157,804	'	'
Deposit	'	'	250,000	'	'
Closing payment	'	'	250,000	'	'
Additional payment amount	'	'	500,000	'	'
Secured note	'	'	2,500,000	'	'
Convertible shares	'	'	625,000	'	'
Quarterly installment	'	'	416,667	'	'
Series I preferres shares issued	'	'	669,708	'	'
Series I conversion into Class A Common Shares	'	'	2,678,832	'	'
Class A common percent of deemed shares	'	'	19.00%	'	'
Class A price per share	'	'	$1	'	'
Royalty due to company on future net sales, rate	'	'	6.00%	'	'
Carrying value, equity investment, beginning balance	'	'	2,157,804	1,887,844	2,157,804
Cash payment received	'	'	500,000	'	'
Partial payment received	'	'	225,000	'	'
Series I Conversion rate per share	'	$4	'	'	'
Subsequent events	'	'	'	'	'
Outstanding balance of Senior secured convertible note assigned to an unrelated party	2,275,000	'	'	'	'
Transaction amount of note assignment	1,250,000	'	'	'	'
Legal fees	7,500	'	'	'	'
NeutriSci Preferred shares due to an unrelated party	500,000	'	'	'	'
Placement agent cash fee	150,000	'	'	'	'
NeutriSci Preferred shares due to Palladium	50,000	'	'	'	'
Net proceeds of note assignment	$1,092,500	'	'	'	'

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	Dec. 28, 2013	Dec. 29, 2012
Intangible assets	'	'
Gross Carrying Amount	$1,075,285	$986,285
Accumulated Amortization	$873,635	$850,103

Intangible_Assets_Details_1

Intangible Assets (Details 1) (USD $)	Dec. 28, 2013
Finite Lived Intangible Assets Future Amortization Expense	'
2014	$28,000
2015	28,000
2016	28,000
2017	28,000
2018	23,000
Thereafter	67,000
Intangible assets	$202,000

Intangible_Assets_Details_Narr

Intangible Assets (Details Narrative) (USD $)	12 Months Ended
	Dec. 28, 2013	Dec. 29, 2012
Intangible Assets Details Narrative	'	'
Amortization expense on amortizable intangible assets	$23,532	$15,934
Unamortized expense to be recognized over a weighted average period	'7 years 10 months 24 days	'

Leasehold_Improvements_and_Equ2

Leasehold Improvements and Equipment (Details) (USD $)	Dec. 28, 2013	Dec. 29, 2012
Leasehold Improvements and Equipment	'	'
Laboratory equipment	$2,782,364	$2,439,688
Leasehold improvements	491,125	403,971
Computer equipment	372,851	363,739
Furniture and fixtures	18,313	18,313
Office equipment	7,877	7,877
Construction in progress	40,126	106,080
Leasehold Improvements and Equipment-gross	3,712,656	3,339,668
Less accumulated depreciation	2,649,417	2,403,242
Leasehold Improvements and Equipment-net	$1,063,239	$936,426

Leasehold_Improvements_and_Equ3

Leasehold Improvements and Equipment (Details Narrative) (USD $)	12 Months Ended
	Dec. 28, 2013	Dec. 29, 2012
Leasehold Improvements And Equipment Details Narrative	'	'
Depreciation expense	$246,175	$328,099

Capitalized_Lease_Obligations_1

Capitalized Lease Obligations (Details) (USD $)	Dec. 28, 2013
Capitalized Lease Obligations Details	'
2014	$172,948
2015	112,794
2016	99,902
2017	79,054
2018	30,198
Total minimum lease payments	494,896
Less amount representing interest at a rate of approximately 9.8% per year	75,667
Present value of net minimum lease payments	419,229
Less current portion	138,887
Long-term obligations under capital leases	$280,342

Capitalized_Lease_Obligations_2

Capitalized Lease Obligations (Details Narrative) (USD $)	12 Months Ended
	Dec. 28, 2013	Dec. 29, 2012
Capitalized Lease Obligations Details Narrative	'	'
Interest expense	$34,330	$29,006

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
	Dec. 28, 2013	Dec. 29, 2012
Income Taxes Details	'	'
Income tax expense (benefit) at statutory rate	($1,503,000)	($3,965,000)
State income taxes, net of federal tax effect	-189,000	-428,000
Nondeductible expenses	117,000	134,000
Change in effective tax rate	-166,000	194,000
Change in valuation allowance	1,732,000	4,136,000
Other	9,000	-71,000
Income Tax Expense Benefit	'	'

Income_Taxes_Details_1

Income Taxes (Details 1) (USD $)	Dec. 28, 2013	Dec. 29, 2012
Deferred tax assets:	'	'
Net operating loss carryforward	$8,953,000	$8,512,000
Stock options and restricted stock	1,945,000	1,679,000
Investment in affiliate related to BluScience transaction	1,187,000	'
Inventory reserve	100,000	138,000
Allowance for doubtful accounts	3,000	169,000
Accrued expenses	164,000	134,000
Intangibles	36,000	48,000
Deferred rent	99,000	76,000
Deferred Tax Assets Gross	12,487,000	10,756,000
Less valuation allowance	12,361,000	10,629,000
Deferred Tax Assets Net	126,000	127,000
Deferred tax liabilities:	'	'
Leasehold improvements and equipment	-100,000	-101,000
Prepaid expenses	-26,000	-26,000
Deferred Income Tax Liabilities	-126,000	-127,000
Deferred Tax Liabilities	'	'

Income_Taxes_Details_Narrative

Income Taxes (Details Narrative) (USD $)	12 Months Ended
	Dec. 28, 2013
Income Taxes Details Narrative	'
Statutory federal income tax rate	34.00%
Federal tax net operating loss carryforwards	$23,329,000
State tax net operating loss carryforwards	$19,227,000

Employee_Equity_Incentive_Plan2

Employee Equity Incentive Plan (Details) (Options [Member])	12 Months Ended
	Dec. 28, 2013	Dec. 29, 2012
Options [Member]	'	'
Volatility	32.75%	33.22%
Expected dividends	0.00%	0.00%
Expected term	'6 years	'5 years 9 months 18 days
Risk-free rate	1.51%	0.96%

Employee_Equity_Incentive_Plan3

Employee Equity Incentive Plan (Details 1) (ServicePeriodBasedStockOptions [Member], USD $)	12 Months Ended
	Dec. 28, 2013
ServicePeriodBasedStockOptions [Member]	'
Number of Shares	'
Outstanding at Beginning of Period	12,202,558
Options Granted	805,000
Options Exercised	-26,038
Options Expired	-75,000
Options Forfeited	-792,865
Outstanding at End of Period	12,113,655
Exercisable at End of Period	8,184,312
Weighted Average Exercise Price	'
Outstanding at Beginning of Period	$1.08
Options Granted	$0.81
Options Exercised	$0.51
Options Expired	$0.50
Options Forfeited	$1.19
Outstanding at End of Period	$1.06
Exercisable at End of Period	$1.14
Weighted Average Remaining Contractual Term	'
Outstanding at End of Period	'7 years 5 months 5 days
Exercisable at End of Period	'6 years 9 months 4 days
Aggregate Intrinsic Value	'
Outstanding at End of Period	$6,513,219
Exercisable at End of Period	$3,767,235

Employee_Equity_Incentive_Plan4

Employee Equity Incentive Plan (Details 2) (Performance Based Stock Options [Member], USD $)	12 Months Ended
	Dec. 28, 2013
Performance Based Stock Options [Member]	'
Summary of performance based stock option activity- Shares	'
Outstanding at Beginning of Period	145,834
Options Granted	200,000
Options Exercised	'
Options Expired	'
Options Forfeited	-145,834
Outstanding at End of Period	200,000
Exercisable at End of Period	'
Weighted Average Exercise Price	'
Outstanding at Beginning of Period	$1.59
Options Granted	$0.63
Options Exercised	'
Options Expired	'
Options Forfeited	$1.59
Outstanding at End of Period	$0.63
Exercisable at End of Period	'
Weighted Average Remaining Contractual Term	'
Outstanding at End of Period	'9 years 29 days
Aggregate Intrinsic Value	'
Outstanding at End of Period	$194,000
Exercisable at End of Period	'

Employee_Equity_Incentive_Plan5

Employee Equity Incentive Plan (Details 3) (Restricted Stock [Member], USD $)	12 Months Ended
	Dec. 28, 2013
Restricted Stock [Member]	'
Summary of activity of restricted stock awards granted to employees- Shares	'
Unvested shares at Beginning of Period	500,000
Granted	'
Vested	'
Forfeited	'
Unvested shares at End of Period	500,000
Expected to Vest as of End of Period	500,000
Weighted Average Award-Date Fair Value	'
Unvested shares at Beginning of Period	$0.69
Granted	'
Vested	'
Forfeited	'
Unvested shares at End of Period	$0.69
Expected to Vest as of End of Period	$0.69

Employee_Equity_Incentive_Plan6

Employee Equity Incentive Plan (Details 4)	12 Months Ended
	Dec. 29, 2012
Weighted average assumptions for restricted stock granted to employees	'
Expected Term	'3 years
Volatility	69.98%
Expected dividends	0.00%
Risk-free rate	0.39%

Employee_Equity_Incentive_Plan7

Employee Equity Incentive Plan (Details Narrative) (USD $)	12 Months Ended
	Dec. 28, 2013	Dec. 29, 2012	Dec. 28, 2013	Dec. 29, 2012	Dec. 28, 2013	Dec. 29, 2012	Dec. 28, 2013	Dec. 29, 2012
	General and Administrative Expense [Member]	General and Administrative Expense [Member]	Options [Member]	Options [Member]	ServicePeriodBasedStockOptions [Member]	ServicePeriodBasedStockOptions [Member]	Performance Based Stock Options [Member]	Accredited Investor Options [Member]
Employee Share-Based Compensation	'	'	'	'	'	'	'	'
Stock option awards, price per share	'	'	'	'	'	'	'	$0.95
Stock option award, termination price per share	'	'	'	'	'	'	'	$1.50
Stock option awards, initial grant	'	'	'	'	'	'	'	7,765,512
Stock option awards, exchange options	'	'	'	'	'	'	'	4,777,878
Expiration dates for stock options not exceeds	'	'	'10 years	'	'	'	'	'
Authorized stock options	'	'	20.00%	'	'	'	'	'
Remaining amount available for issuance	'	'	6,953,940	'	'	'	'	'
Closing stock price	'	'	'	'	$1.60	'	$1.60	'
Aggregate intrinsic value of options exercised	'	'	'	'	$7,000	$1,000	'	'
Unrecognized compensation expense	'	'	1,628,000	'	'	'	'	'
Cost is expected to be recognized over a weighted average period	'	'	'P2Y3M25D	'	'	'	'	'
Weighted average fair value of options granted	'	'	'	'	$0.29	$0.27	$0.22	'
Realized tax benefit from stock options	'	'	0	0	'	'	'	'
Recognized share based compensation expense (income)	$958,000	$1,498,000	'	'	'	'	'	$970,071

Employee_Equity_Incentive_Plan8

Employee Equity Incentive Plan (Details Narrative 2) (USD $)	12 Months Ended
	Dec. 29, 2012
Spengler [Member]	'
Employee Share Based Compensation - Restricted Stock	'
Shares forfeited	1,000,000
Reversed expense amount	$476,411
Himmel [Member]	'
Employee Share Based Compensation - Restricted Stock	'
Shares forfeited	1,000,000
Shares granted	1,000,000
Employee Share Based Compensation - Stock Awards	'
Shares granted stock awards	100,000
Expensed on date of award	94,000
Heim [Member]	'
Employee Share Based Compensation - Restricted Stock	'
Shares forfeited	750,000
Shares granted	750,000
Employee Share Based Compensation - Stock Awards	'
Shares granted stock awards	75,000
Expensed on date of award	60,000
Jaksch [Member]	'
Employee Share Based Compensation - Restricted Stock	'
Shares granted	250,000
Varvaro [Member]	'
Employee Share Based Compensation - Restricted Stock	'
Shares granted	250,000
Brauser [Member]	'
Employee Share Based Compensation - Stock Awards	'
Shares granted stock awards	500,000
Expensed on date of award	345,000
Honig [Member]	'
Employee Share Based Compensation - Stock Awards	'
Shares granted stock awards	500,000
Expensed on date of award	$345,000

NonEmployee_ShareBased_Compens2

Non-Employee Share-Based Compensation (Details) (USD $)	12 Months Ended
	Dec. 28, 2013
Non-Employee Share-Based Compensation- Options	'
Outstanding at Beginning of Period	1,097,300
Options Granted	'
Options Exercised	-250,000
Options Forfeited	'
Outstanding at End of Period	847,300
Exercisable at End of Period	847,300
Weighted Average Exercise Price	'
Outstanding at Beginning of Period	$1.23
Options Granted	'
Options Exercised	$0.50
Options Forfeited	'
Outstanding at End of Period	$1.44
Exercisable at End of Period	$1.44
Weighted Average Remaining Contractual Term	'
Outstanding at End of Period	'5 years 8 months 12 days
Exercisable at End of Period	'5 years 8 months 12 days
Aggregate Intrinsic Value	'
Outstanding at End of Period	$131,627
Exercisable at End of Period	$131,627

NonEmployee_ShareBased_Compens3

Non-Employee Share-Based Compensation (Details 2)	12 Months Ended
	Dec. 29, 2012
Non-Employee Warrant Award	'
Volatility	28.20%
Expected dividends	0.00%
Expected term	'2 years
Risk-free rate	0.27%

NonEmployee_ShareBased_Compens4

Non-Employee Share-Based Compensation (Details Narrative) (USD $)	12 Months Ended
	Dec. 28, 2013	Dec. 29, 2012
NonEmployee Share Based Compensation [Member] | Stock Options [Member]	'	'
Closing stock price	$1.60	'
Aggregate intrinsic value nonemployee options exercised	$35,000	'
NonEmployee Share Based Compensation [Member] | StockAward [Member]	'	'
Shares awarded during the period	600,000	1,234,851
Share-based compensation expense	325,000	790,000
NonEmployee Shared Based Compensation [Member] | WarrantAward [Member]	'	'
Share-based compensation expense	4,094	4,731
Shares issued upon exercise of warrants	74,186	'
Shares exercisable, if not cashless exercised	250,000	'
Exercise; price per share	$0.75	'
Intrinsic value of warrants exercised	90,507	'
NonEmployee Shared Based Compensation [Member] | GeneralAndAdministrativeExpenses [Member]	'	'
Share-based compensation expense	$330,000	$1,206,000

Stock_Issuance_Details

Stock Issuance (Details)	12 Months Ended
	Dec. 29, 2012
Assumptions for the warrants issued to Aegis Capital Corp	'
Volatility	29.70%
Expected dividends	0.00%
Expected term	'2 years 6 months
Risk-free rate	0.28%

Stock_Issuance_Details_Narrati

Stock Issuance (Details Narrative) (USD $)	Feb. 10, 2012	Feb. 09, 2012	Jan. 31, 2012	Dec. 28, 2013	Dec. 28, 2013
				Sale of Stock 1 [Member]	Sale of Stock 2 [Member]
Registered direct offering of common stock	'	'	$0.75	'	'
Restricted shares of common stock price per share	'	'	$0.75	'	'
Common stock price per share	'	$0.75	$0.75	'	'
Gross proceeds from sale of common stock	$3,699,997	$7,475,000	'	'	'
Gross proceeds after deducting offering costs	3,330,740	6,739,498	'	'	'
Restricted shares of common stock sold	4,933,329	'	'	'	'
Shares of common stock sold	'	9,966,666	'	'	'
Restricted shares price per share	$0.75	'	'	'	'
Warrants issued to Placement agent	'	300,000	'	'	'
Exercise price of warrants	'	$0.85	'	'	'
Term of warrants	'	'P2Y6M	'	'	'
Fair value of warrants	'	44,610	'	'	'
Number of shares issued	'	'	'	2,941,176	588,235
Proceeds to company	'	'	'	2,500,000	500,000
Common stock price per share	'	'	'	$0.85	$0.85
Placement agent fee	'	'	'	'	$20,000

Warrants_Details

Warrants (Details) (USD $)	12 Months Ended
	Dec. 28, 2013
Warrants Details	'
Warrants outstanding at beginning of period	10,056,914
Warrants granted	'
Warrants exercised	-8,338,564
Warrants expired	-1,718,350
Warrants outstanding at end of period	'
Warrants exercisable at end of period	'
Weighted Average Exercise Price	'
Outstanding at beginning of period	$0.72
Warrants Granted	'
Warrants exercised	$0.25
Warrant expired	$3
Outstanding at end of period	'
Exercisable at end of period	'

Warrants_Details_Narrative

Warrants (Details Narrative) (USD $)	12 Months Ended
	Dec. 28, 2013	Dec. 29, 2012
Warrants awarded	'	'
Proceeds from exercise of warrants	$1,638,748	$157,500
$0.21 per Share [Member]	'	'
Exercise of warrants, shares	7,803,564	750,000
Exercise price of warrant	$0.21	$0.21
Proceeds from exercise of warrants	$1,638,748	$157,500
$0.75 per Share [Member]	'	'
Warrants awarded	'	250,000
Exercise price of warrant	$0.75	$0.75
Warrant term	'	'2 years
Shares issued upon exercise of warrants	74,186	'
Shares exercisable, if not cashless exercised	250,000	'
$0.85 per Share [Member]	'	'
Warrants awarded	'	300,000
Exercise price of warrant	$0.85	$0.85
Shares issued upon exercise of warrants	101,477	4,103
Shares exercisable, if not cashless exercised	285,000	15,000

Commitments_and_Contingencies_

Commitments and Contingencies (Details) (USD $)	Dec. 28, 2013
Minimum Future Rental Payments	'
2014	$524,000
2015	515,000
2016	319,000
2017	225,000
2018	233,000
Minimum future rental payments	$1,816,000

Commitments_and_Contingencies_1

Commitments and Contingencies (Details 1) (USD $)	Dec. 28, 2013
Minimum Future Royalties	'
2014	$150,000
2015	179,000
2016	199,000
2017	200,000
2018	200,000
Minimum royalties including license maintenance fees	$929,000

Commitments_and_Contingencies_2

Commitments and Contingencies (Details Narrative) (USD $)	12 Months Ended
	Dec. 28, 2013	Dec. 29, 2012
Lease	'	'
Rent expense	$519,000	$512,000
Royalty	'	'
Royalty expense including license maintenance fees	111,000	75,000
Jaksch [Member]	'	'
Severance payments to executive officers	'	'
Employment agreement term	'3 years	'
Salary	275,000	'
Maximum Bonus target	50.00%	'
Bonus rate for Severance	50.00%	'
Severance term, paid salary, voluntary	'3 months 20 days	'
Severance term, paid salary, with release	'12 months	'
Severance term, paid salary, Cessation of business	'12 months	'
Severance term, paid salary, without cause	'1 month 25 days	'
Severance term, paid salary, without cause, separation agreement	'2 years	'
Varvaro [Member]	'	'
Severance payments to executive officers	'	'
Employment agreement term	'3 years	'
Salary	225,000	'
Maximum Bonus target	40.00%	'
Bonus rate for Severance	40.00%	'
Severance term, paid salary, voluntary	'3 months 20 days	'
Severance term, paid salary, with release	'12 months	'
Severance term, paid salary, Cessation of business	'12 months	'
Severance term, paid salary, without cause	'1 month 25 days	'
Severance term, paid salary, without cause, separation agreement	'2 years	'
Minimum [Member]	'	'
Lease	'	'
Monthly lease payment	1,214	'
Royalty	'	'
Minimum yearly royalty payments	1,000	'
Royalty payable on sales	2.00%	'
Maximum [Member]	'	'
Lease	'	'
Monthly lease payment	22,124	'
Royalty	'	'
Minimum yearly royalty payments	35,000	'
Royalty increase	$50,000	'
Royalty payable on sales	5.00%	'

Business_Segmentation_and_Geog2

Business Segmentation and Geographical Distribution (Details) (USD $)	12 Months Ended								9 Months Ended	12 Months Ended
	Dec. 28, 2013	Dec. 29, 2012	Dec. 28, 2013	Dec. 29, 2012	Dec. 28, 2013	Dec. 29, 2012	Dec. 28, 2013	Dec. 29, 2012	Sep. 29, 2012	Dec. 28, 2013
			CoreStandardsContractServices [Member]	CoreStandardsContractServices [Member]	ScientificRegulatory [Member]	ScientificRegulatory [Member]	Scientific Regulatory [Member]	Scientific Regulatory [Member]	Other Segment [Member]	Other Segment [Member]
Net sales	$10,160,964	$11,610,494	$9,074,531	$8,458,082	$1,146,718	$69,718	($60,285)	$3,082,694	'	'
Cost of sales	7,027,828	9,335,057	6,394,836	6,075,050	632,037	25,729	955	3,235,278	'	'
Gross profit (loss)	3,133,136	2,275,437	2,679,698	2,383,032	514,681	43,989	-61,240	-151,584	'	'
Sales and marketing	2,357,605	5,520,141	2,211,741	2,227,934	14,705	'	131,159	3,292,207	'	'
General and Administrative	5,117,016	8,391,730	'	'	'	'	'	'	8,391,730	5,117,016
Loss from investment in affiliate	44,961	'	'	'	'	'	'	'	'	44,961
Operating expenses	7,519,582	13,911,871	2,211,741	2,227,934	14,705	'	131,159	3,292,207	8,391,730	5,161,977
Operating income (loss)	($4,386,446)	($11,636,434)	$467,954	$155,098	$499,976	$43,989	($192,399)	($3,443,791)	($8,391,730)	($5,161,977)

Business_Segmentation_and_Geog3

Business Segmentation and Geographical Distribution (Details1) (USD $)	Dec. 28, 2013	Dec. 29, 2012
Total assets	$8,986,892	$9,034,521
CoreStandardsContractServices [Member]	'	'
Total assets	4,036,126	3,542,355
ScientificRegulatory [Member]	'	'
Total assets	139,765	72,573
Scientific Regulatory [Member]	'	'
Total assets	'	4,331,866
Other Segment [Member]	'	'
Total assets	$4,811,001	$1,087,727

Business_Segmentation_and_Geog4

Business Segmentation and Geographical Distribution (Details Narrative) (USD $)	12 Months Ended
	Dec. 28, 2013	Dec. 29, 2012
CoreStandardsContractServices [Member]	'	'
Revenue from international sources	$1,510,000	$1,690,000
Scientific Regulatory [Member]	'	'
Revenue from international sources	$450,000	$4,000

RelatedParty_Transactions_Deta

Related-Party Transactions (Details Narrative) (USD $)	Dec. 28, 2013	Dec. 29, 2012
Related Transactions Details Narrative	'	'
Fair value of stock award	'	$320,000
Shares granted in consideration for services	'	500,000
Beneficial ownership in terms of shares	15,252,937	'
Beneficial ownership in terms of shares in percentage	14.50%	'

Subsequent_Events_Details_Narr

Subsequent Events (Details Narrative) (USD $)	3 Months Ended
	Mar. 26, 2014
Subsequent Events Details Narrative	'
Senior secured convertible note assigned to an unrelated party	$2,275,000
Transaction amount of note assignment	1,250,000
Net proceeds of note assignment	1,092,500
Legal fee	7,500
NeutriSci Preferred shares due to an unrelated party	500,000
NeutriSci Preferred Shares due to Palladium	$50,000
Restricted stock award	1,090,000